Hypoxia	O
causes	O
the	O
activation	O
of	O
nuclear	B-protein
factor	I-protein
kappa	I-protein
B	I-protein
through	O
the	O
phosphorylation	O
of	O
I	B-protein
kappa	I-protein
B	I-protein
alpha	I-protein
on	O
tyrosine	O
residues	O
.	O

The	O
response	O
of	O
mammalian	B-cell_type
cells	I-cell_type
to	O
stress	O
is	O
controlled	O
by	O
transcriptional	B-protein
regulatory	I-protein
proteins	I-protein
such	O
as	O
nuclear	B-protein
factor	I-protein
kappa	I-protein
B	I-protein
(	O
NF-kappa	B-protein
B	I-protein
)	O
to	O
induce	O
a	O
wide	O
variety	O
of	O
early	B-DNA
response	I-DNA
genes	I-DNA
.	O

In	O
this	O
report	O
,	O
we	O
show	O
that	O
exposure	O
of	O
cells	O
to	O
hypoxia	O
(	O
0.02	O
%	O
O2	O
)	O
results	O
in	O
I	B-protein
kappa	I-protein
B	I-protein
alpha	I-protein
degradation	O
,	O
increased	O
NF-kappa	B-protein
B	I-protein
DNA	O
binding	O
activity	O
,	O
and	O
transactivation	O
of	O
a	O
reporter	B-DNA
gene	I-DNA
construct	I-DNA
containing	O
two	O
NF-kappa	B-DNA
B	I-DNA
DNA	I-DNA
binding	I-DNA
sites	I-DNA
.	O

Pretreatment	O
of	O
cells	O
with	O
protein	O
tyrosine	B-protein
kinase	I-protein
inhibitors	O
and	O
the	O
dominant	B-DNA
negative	I-DNA
allele	I-DNA
of	O
c-Raf-1	B-DNA
(	O
Raf	B-protein
301	I-protein
)	O
inhibited	O
I	B-protein
kappa	I-protein
B	I-protein
alpha	I-protein
degradation	O
,	O
NF-kappa	B-protein
B	I-protein
binding	O
,	O
and	O
transactivation	O
of	O
kappa	B-DNA
B	I-DNA
reporter	I-DNA
constructs	I-DNA
by	O
hypoxia	O
.	O

To	O
demonstrate	O
a	O
direct	O
link	O
between	O
changes	O
in	O
the	O
phosphorylation	O
pattern	O
of	O
I	B-protein
kappa	I-protein
B	I-protein
alpha	I-protein
with	O
NF-kappa	B-protein
B	I-protein
activation	O
,	O
we	O
immunoprecipitated	O
I	B-protein
kappa	I-protein
B	I-protein
alpha	I-protein
after	O
varying	O
times	O
of	O
hypoxic	O
exposure	O
and	O
found	O
that	O
its	O
tyrosine	O
phosphorylation	O
status	O
increased	O
during	O
hypoxic	O
exposure	O
.	O

Inhibition	O
of	O
the	O
transfer	O
of	O
tyrosine	O
phosphoryl	O
groups	O
onto	O
I	B-protein
kappa	I-protein
B	I-protein
alpha	I-protein
prevented	O
I	B-protein
kappa	I-protein
B	I-protein
alpha	I-protein
degradation	O
and	O
NF-kappa	B-protein
B	I-protein
binding	O
.	O

In	O
comparison	O
to	O
other	O
activators	O
of	O
NF-kappa	B-protein
B	I-protein
such	O
as	O
phorbol	O
myristate	O
acetate	O
or	O
tumor	B-protein
necrosis	I-protein
factor	I-protein
,	O
we	O
did	O
not	O
detect	O
changes	O
in	O
the	O
tyrosine	O
phosphorylation	O
status	O
of	O
I	B-protein
kappa	I-protein
B	I-protein
alpha	I-protein
following	O
treatment	O
with	O
either	O
of	O
these	O
agents	O
.	O

These	O
results	O
suggest	O
that	O
tyrosine	O
phosphorylation	O
of	O
I	B-protein
kappa	I-protein
B	I-protein
alpha	I-protein
during	O
hypoxia	O
is	O
an	O
important	O
proximal	O
step	O
which	O
precedes	O
its	O
dissociation	O
and	O
degradation	O
from	O
NF-kappa	B-protein
B	I-protein
.	O

[	NULL
CANCER	NULL
RESEARCH	NULL
54	NULL
,	NULL
1425-1430	NULL
,	NULL
March	NULL
15	NULL
,	NULL
1994	NULL
]	NULL
Advances	NULL
in	NULL
Brief	NULL
Hypoxia	NULL
Causes	NULL
the	NULL
Activation	NULL
of	NULL
Nuclear	NULL
Factor	NULL
xB	NULL
through	NULL
the	NULL
Phosphorylation	NULL
of	NULL
IxBa	NULL
on	NULL
Tyrosine	NULL
Residues	NULL
!	NULL

Albert	NULL
C.	NULL
Koong	NULL
,	NULL
Eunice	NULL
Y.	NULL
Chen	NULL
,	NULL
and	NULL
Amato	NULL
J.	NULL
Giaccia*	NULL
Cancer	NULL
Biology	NULL
Research	NULL
Laboratory	NULL
,	NULL
Stanford	NULL
University	NULL
School	NULL
of	NULL
Medicine	NULL
,	NULL
Stanford	NULL
,	NULL
California	NULL
94305-5468	NULL
Abstract	NULL
The	NULL
response	NULL
of	NULL
mammalian	NULL
cells	NULL
to	NULL
stress	NULL
is	NULL
controlled	NULL
by	NULL
transcriptional	NULL
regulatory	NULL
proteins	NULL
such	NULL
as	NULL
nuclear	NULL
factor	NULL
«	NULL
B	NULL
(	NULL
NF-	NULL
«	NULL
B	NULL
)	NULL
to	NULL
induce	NULL
a	NULL
wide	NULL
variety	NULL
of	NULL
early	NULL
response	NULL
genes	NULL
.	NULL

In	NULL
this	NULL
report	NULL
,	NULL
we	NULL
show	NULL
that	NULL
exposure	NULL
of	NULL
cells	NULL
to	NULL
hypoxia	NULL
(	NULL
0.02	NULL
%	NULL
O	NULL
;	NULL
)	NULL
results	NULL
in	NULL
IxBa	NULL
degradation	NULL
,	NULL
increased	NULL
NF-	NULL
«	NULL
B	NULL
DNA	NULL
binding	NULL
activity	NULL
,	NULL
and	NULL
transactivation	NULL
of	NULL
a	NULL
reporter	NULL
gene	NULL
construct	NULL
containing	NULL
two	NULL
NF-	NULL
«	NULL
B	NULL
DNA	NULL
binding	NULL
sites	NULL
.	NULL

Pretreatment	NULL
of	NULL
cells	NULL
with	NULL
protein	NULL
tyrosine	NULL
kinase	NULL
inhibitors	NULL
and	NULL
the	NULL
dominant	NULL
negative	NULL
allele	NULL
of	NULL
c-Raf-1	NULL
(	NULL
Raf	NULL
301	NULL
)	NULL
inhibited	NULL
IxBa	NULL
degradation	NULL
,	NULL
NF-xB	NULL
binding	NULL
,	NULL
and	NULL
transactivation	NULL
of	NULL
xB	NULL
reporter	NULL
constructs	NULL
by	NULL
hypoxia	NULL
.	NULL

To	NULL
demonstrate	NULL
a	NULL
direct	NULL
link	NULL
between	NULL
changes	NULL
in	NULL
the	NULL
phosphorylation	NULL
pattern	NULL
of	NULL
IxBa	NULL
with	NULL
NF-	NULL
«	NULL
B	NULL
activation	NULL
,	NULL
we	NULL
immunoprecipitated	NULL
IxBa	NULL
after	NULL
varying	NULL
times	NULL
of	NULL
hypoxic	NULL
exposure	NULL
and	NULL
found	NULL
that	NULL
its	NULL
tyrosine	NULL
phosphorylation	NULL
status	NULL
increased	NULL
during	NULL
hypoxic	NULL
exposure	NULL
.	NULL

Inhibition	NULL
of	NULL
the	NULL
transfer	NULL
of	NULL
tyrosine	NULL
phosphoryl	NULL
groups	NULL
onto	NULL
IxBa	NULL
prevented	NULL
IxBa	NULL
degradation	NULL
and	NULL
NF-B	NULL
binding	NULL
.	NULL

In	NULL
comparison	NULL
to	NULL
other	NULL
activators	NULL
of	NULL
NF-B	NULL
such	NULL
as	NULL
phorbol	NULL
myristate	NULL
acetate	NULL
or	NULL
tumor	NULL
necrosis	NULL
factor	NULL
,	NULL
we	NULL
did	NULL
not	NULL
detect	NULL
changes	NULL
in	NULL
the	NULL
tyrosine	NULL
phosphorylation	NULL
status	NULL
of	NULL
IxBa	NULL
following	NULL
treatment	NULL
with	NULL
either	NULL
of	NULL
these	NULL
agents	NULL
.	NULL

These	NULL
results	NULL
suggest	NULL
that	NULL
tyrosine	NULL
phosphorylation	NULL
of	NULL
IxBa	NULL
during	NULL
hypoxia	NULL
is	NULL
an	NULL
important	NULL
proximal	NULL
step	NULL
which	NULL
precedes	NULL
its	NULL
dissociation	NULL
and	NULL
degradation	NULL
from	NULL
NF-B	NULL
.	NULL

Introduction	NULL
Cells	NULL
maintain	NULL
homeostasis	NULL
by	NULL
rapidly	NULL
responding	NULL
to	NULL
changes	NULL
in	NULL
the	NULL
extracellular	NULL
environment	NULL
.	NULL

Hypoxia	NULL
,	NULL
the	NULL
condition	NULL
of	NULL
low	NULL
oxygen	NULL
,	NULL
is	NULL
one	NULL
of	NULL
the	NULL
most	NULL
basic	NULL
environmental	NULL
stresses	NULL
that	NULL
a	NULL
cell	NULL
may	NULL
experi-ence	NULL
.	NULL

It	NULL
also	NULL
has	NULL
great	NULL
clinical	NULL
significance	NULL
in	NULL
that	NULL
hypoxic	NULL
cells	NULL
within	NULL
solid	NULL
tumors	NULL
contribute	NULL
to	NULL
the	NULL
treatment	NULL
failure	NULL
of	NULL
conventional	NULL
radiotherapy	NULL
and	NULL
some	NULL
forms	NULL
of	NULL
chemotherapy	NULL
(	NULL
1-3	NULL
)	NULL
.	NULL

By	NULL
invoking	NULL
protective	NULL
mechanisms	NULL
such	NULL
as	NULL
reduced	NULL
macromolecular	NULL
synthesis	NULL
,	NULL
cell	NULL
cycle	NULL
arrest	NULL
,	NULL
and	NULL
selective	NULL
gene	NULL
induction	NULL
,	NULL
both	NULL
transformed	NULL
and	NULL
untrans-formed	NULL
cells	NULL
protect	NULL
themselves	NULL
against	NULL
fluctuations	NULL
in	NULL
environmental	NULL
oxygen	NULL
levels	NULL
.	NULL

A	NULL
number	NULL
of	NULL
genes	NULL
have	NULL
been	NULL
shown	NULL
to	NULL
alter	NULL
their	NULL
expression	NULL
as	NULL
a	NULL
result	NULL
of	NULL
transcription	NULL
factors	NULL
that	NULL
are	NULL
activated	NULL
by	NULL
hypoxia	NULL
.	NULL

Some	NULL
of	NULL
these	NULL
genes/transcription	NULL
factors	NULL
include	NULL
glucose-regulated	NULL
M	NULL
,	NULL
78,000	NULL
protein	NULL
by	NULL
a	NULL
glucose-responsive	NULL
element	NULL
(	NULL
4	NULL
,	NULL
5	NULL
)	NULL
,	NULL
erythropoietin	NULL
by	NULL
hypoxia-inducible	NULL
factor	NULL
1	NULL
(	NULL
6	NULL
,	NULL
7	NULL
)	NULL
,	NULL
and	NULL
heat	NULL
shock	NULL
protein	NULL
70	NULL
by	NULL
the	NULL
heat	NULL
shock	NULL
factor	NULL
(	NULL
8	NULL
)	NULL
.	NULL

However	NULL
,	NULL
little	NULL
is	NULL
known	NULL
about	NULL
the	NULL
cellular	NULL
signals	NULL
which	NULL
mediate	NULL
the	NULL
activation	NULL
of	NULL
transcription	NULL
factors	NULL
by	NULL
hypoxia	NULL
.	NULL

A	NULL
growing	NULL
number	NULL
of	NULL
stress-inducible	NULL
genes	NULL
have	NULL
been	NULL
shown	NULL
to	NULL
increase	NULL
their	NULL
expression	NULL
through	NULL
the	NULL
activation	NULL
of	NULL
the	NULL
transcription	NULL
factor	NULL
NF-	NULL
«	NULL
B°	NULL
(	NULL
9-11	NULL
)	NULL
.	NULL

A	NULL
common	NULL
feature	NULL
of	NULL
these	NULL
early	NULL
response	NULL
genes	NULL
is	NULL
that	NULL
their	NULL
relatively	NULL
rapid	NULL
induction	NULL
may	NULL
be	NULL
attributed	NULL
to	NULL
the	NULL
Received	NULL
1/14/94	NULL
;	NULL
accepted	NULL
2/4/94	NULL
.	NULL

The	NULL
costs	NULL
of	NULL
publication	NULL
of	NULL
this	NULL
article	NULL
were	NULL
defrayed	NULL
in	NULL
part	NULL
by	NULL
the	NULL
payment	NULL
of	NULL
page	NULL
charges	NULL
.	NULL

This	NULL
article	NULL
must	NULL
therefore	NULL
be	NULL
hereby	NULL
marked	NULL
advertisement	NULL
in	NULL
accordance	NULL
with	NULL
18	NULL
U.S.C	NULL
.	NULL

Section	NULL
1734	NULL
solely	NULL
to	NULL
indicate	NULL
this	NULL
fact	NULL
.	NULL
'	NULL

This	NULL
work	NULL
was	NULL
supported	NULL
by	NULL
Grant	NULL
CAO3353	NULL
from	NULL
the	NULL
National	NULL
Cancer	NULL
Institute	NULL
to	NULL
A.	NULL
J.	NULL
G.	NULL
and	NULL
a	NULL
NIH	NULL
Predoctoral	NULL
Training	NULL
Grant	NULL
to	NULL
A.	NULL
C.	NULL
K.	NULL
*	NULL
To	NULL
whom	NULL
requests	NULL
for	NULL
reprints	NULL
should	NULL
be	NULL
addressed	NULL
.	NULL

>	NULL
The	NULL
abbreviations	NULL
used	NULL
are	NULL
:	NULL
NF-KB	NULL
,	NULL
nuclear	NULL
factor	NULL
«	NULL
B	NULL
;	NULL
HIV	NULL
,	NULL
human	NULL
immunodeficiency	NULL
virus	NULL
;	NULL
TNF	NULL
,	NULL
tumor	NULL
necrosis	NULL
factor	NULL
;	NULL
CAT	NULL
,	NULL
chloramphenicol	NULL
acetyltransferase	NULL
;	NULL
PMA	NULL
,	NULL
phorbol	NULL
myristate	NULL
acetate	NULL
;	NULL
SDS	NULL
,	NULL
sodium	NULL
dodecyl	NULL
sulfate	NULL
;	NULL
Hepes	NULL
,	NULL
4-	NULL
(	NULL
2-hydroxyethyl	NULL
)	NULL
-1-piperazineethanesulfonic	NULL
acid	NULL
;	NULL
DTT	NULL
,	NULL
dithiothreitol	NULL
.	NULL

fact	NULL
that	NULL
NF-	NULL
«	NULL
B	NULL
activation	NULL
of	NULL
gene	NULL
transcription	NULL
does	NULL
not	NULL
require	NULL
de	NULL
novo	NULL
protein	NULL
synthesis	NULL
.	NULL

This	NULL
feature	NULL
of	NULL
genes	NULL
possessing	NULL
NF-	NULL
«	NULL
B	NULL
binding	NULL
sites	NULL
allows	NULL
them	NULL
to	NULL
be	NULL
well	NULL
suited	NULL
for	NULL
the	NULL
rapid	NULL
synthesis	NULL
of	NULL
protective	NULL
and	NULL
signaling	NULL
proteins	NULL
after	NULL
exposure	NULL
to	NULL
a	NULL
wide	NULL
variety	NULL
of	NULL
stresses	NULL
(	NULL
12-14	NULL
)	NULL
.	NULL

Understanding	NULL
the	NULL
activation	NULL
of	NULL
NF-	NULL
«	NULL
B	NULL
has	NULL
become	NULL
increasingly	NULL
more	NULL
complicated	NULL
with	NULL
the	NULL
discovery	NULL
of	NULL
an	NULL
entire	NULL
family	NULL
of	NULL
transcription	NULL
factors	NULL
that	NULL
autoregulate	NULL
themselves	NULL
through	NULL
subunit	NULL
interaction	NULL
(	NULL
13	NULL
,	NULL
15-20	NULL
)	NULL
.	NULL

The	NULL
regulation	NULL
of	NULL
the	NULL
most	NULL
common	NULL
form	NULL
of	NULL
NF-	NULL
«	NULL
B	NULL
involves	NULL
the	NULL
interaction	NULL
of	NULL
at	NULL
least	NULL
three	NULL
distinct	NULL
subunits	NULL
,	NULL
p50	NULL
,	NULL
p65	NULL
,	NULL
and	NULL
IkBa	NULL
.	NULL

In	NULL
the	NULL
cytoplasm	NULL
,	NULL
the	NULL
major	NULL
form	NULL
of	NULL
NF-	NULL
«	NULL
B	NULL
is	NULL
found	NULL
in	NULL
its	NULL
inactive	NULL
state	NULL
with	NULL
the	NULL
inhibitory	NULL
subunit	NULL
,	NULL
IxBa	NULL
,	NULL
bound	NULL
to	NULL
the	NULL
p50-p65	NULL
heterodimer	NULL
(	NULL
12	NULL
)	NULL
.	NULL

Upon	NULL
activation	NULL
,	NULL
IxBa	NULL
is	NULL
cleaved	NULL
from	NULL
the	NULL
complex	NULL
,	NULL
and	NULL
the	NULL
p50-p65	NULL
heterodimer	NULL
complex	NULL
is	NULL
translocated	NULL
from	NULL
the	NULL
cytoplasm	NULL
to	NULL
the	NULL
nucleus	NULL
where	NULL
it	NULL
binds	NULL
with	NULL
high	NULL
affinity	NULL
to	NULL
a	NULL
«	NULL
B	NULL
motif	NULL
.	NULL

It	NULL
is	NULL
thought	NULL
that	NULL
the	NULL
mammalian	NULL
ReI/NF-	NULL
«	NULL
B	NULL
proteins	NULL
form	NULL
homo-	NULL
and	NULL
heterodimers	NULL
between	NULL
different	NULL
subunits	NULL
which	NULL
bind	NULL
with	NULL
different	NULL
affinities	NULL
to	NULL
variants	NULL
of	NULL
the	NULL
«	NULL
B	NULL
motif	NULL
as	NULL
a	NULL
mechanism	NULL
of	NULL
regulating	NULL
the	NULL
cellular	NULL
response	NULL
to	NULL
subtle	NULL
changes	NULL
in	NULL
the	NULL
environment	NULL
(	NULL
9-11	NULL
,	NULL
21	NULL
)	NULL
.	NULL

A	NULL
further	NULL
means	NULL
to	NULL
regulate	NULL
the	NULL
Rel/NF-	NULL
«	NULL
B	NULL
proteins	NULL
is	NULL
accomplished	NULL
through	NULL
interactions	NULL
with	NULL
different	NULL
forms	NULL
of	NULL
I	NULL
«	NULL
Ba	NULL
,	NULL
-B	NULL
,	NULL
-y	NULL
,	NULL
and	NULL
bel-3	NULL
(	NULL
22-28	NULL
)	NULL
.	NULL

What	NULL
are	NULL
the	NULL
signals	NULL
which	NULL
cause	NULL
the	NULL
dissociation	NULL
and	NULL
depletion	NULL
of	NULL
IxBa	NULL
and	NULL
the	NULL
nuclear	NULL
translocation	NULL
of	NULL
NF-	NULL
«	NULL
B	NULL
?	NULL

In	NULL
vitro	NULL
studies	NULL
have	NULL
shown	NULL
that	NULL
phosphorylation	NULL
of	NULL
the	NULL
IxBa	NULL
subunit	NULL
causes	NULL
it	NULL
to	NULL
dissociate	NULL
from	NULL
the	NULL
p50-p65	NULL
complex	NULL
(	NULL
29	NULL
)	NULL
.	NULL

Although	NULL
protein	NULL
kinase	NULL
C	NULL
has	NULL
been	NULL
implicated	NULL
as	NULL
one	NULL
of	NULL
the	NULL
kinases	NULL
responsible	NULL
for	NULL
the	NULL
activation	NULL
of	NULL
NF-	NULL
«	NULL
B	NULL
,	NULL
it	NULL
most	NULL
likely	NULL
is	NULL
not	NULL
the	NULL
sole	NULL
kinase	NULL
involved	NULL
in	NULL
this	NULL
pathway	NULL
.	NULL

Other	NULL
in	NULL
vitro	NULL
studies	NULL
provide	NULL
evidence	NULL
that	NULL
a	NULL
cyclic	NULL
AMP-dependent	NULL
kinase	NULL
and	NULL
a	NULL
heme-regulated	NULL
kinase	NULL
may	NULL
also	NULL
play	NULL
a	NULL
role	NULL
in	NULL
triggering	NULL
NF-	NULL
«	NULL
B	NULL
activation	NULL
(	NULL
29	NULL
,	NULL
30	NULL
)	NULL
.	NULL

Phosphorylation	NULL
of	NULL
IxBa	NULL
has	NULL
also	NULL
been	NULL
demonstrated	NULL
in	NULL
vivo	NULL
,	NULL
but	NULL
the	NULL
identity	NULL
of	NULL
the	NULL
amino	NULL
acids	NULL
phosphorylated	NULL
(	NULL
e.g	NULL
.	NULL

,	NULL
serine	NULL
,	NULL
threonine	NULL
,	NULL
and/or	NULL
tyrosine	NULL
)	NULL
and	NULL
the	NULL
significance	NULL
of	NULL
this	NULL
phosphorylation	NULL
are	NULL
still	NULL
unclear	NULL
(	NULL
31	NULL
)	NULL
.	NULL

In	NULL
summary	NULL
,	NULL
the	NULL
data	NULL
taken	NULL
from	NULL
several	NULL
groups	NULL
suggests	NULL
that	NULL
reactive	NULL
oxygen	NULL
intermediates	NULL
cause	NULL
the	NULL
activation	NULL
of	NULL
membrane	NULL
associated	NULL
kinases	NULL
such	NULL
as	NULL
src	NULL
,	NULL
ras	NULL
,	NULL
and	NULL
raf	NULL
.	NULL

These	NULL
membrane-associated	NULL
kinases	NULL
signal	NULL
other	NULL
unknown	NULL
kinase	NULL
(	NULL
s	NULL
)	NULL
which	NULL
ultimately	NULL
lead	NULL
to	NULL
the	NULL
dissociation	NULL
of	NULL
IxBa	NULL
and	NULL
the	NULL
activation	NULL
of	NULL
NF-	NULL
«	NULL
B	NULL
.	NULL

Delineation	NULL
of	NULL
the	NULL
pathway	NULL
leading	NULL
to	NULL
NF-KB	NULL
activation	NULL
by	NULL
hypoxia	NULL
has	NULL
important	NULL
implications	NULL
not	NULL
only	NULL
in	NULL
understanding	NULL
how	NULL
HIV-1	NULL
viral	NULL
replication	NULL
is	NULL
enhanced	NULL
by	NULL
low	NULL
oxygen	NULL
conditions	NULL
(	NULL
32	NULL
)	NULL
but	NULL
also	NULL
for	NULL
investigating	NULL
how	NULL
the	NULL
regulation	NULL
of	NULL
genes	NULL
which	NULL
contain	NULL
NF-	NULL
«	NULL
B-binding	NULL
sites	NULL
are	NULL
involved	NULL
in	NULL
the	NULL
immune	NULL
response	NULL
and	NULL
angiogenesis	NULL
(	NULL
i.e	NULL
.	NULL

,	NULL
TNFa	NULL
,	NULL
interleukin	NULL
2	NULL
,	NULL
interleukin	NULL
6	NULL
,	NULL
and	NULL
vascular	NULL
cell	NULL
adhesion	NULL
molecule	NULL
1	NULL
)	NULL
.	NULL

Since	NULL
one	NULL
common	NULL
feature	NULL
of	NULL
many	NULL
solid	NULL
tumors	NULL
is	NULL
that	NULL
fluctuations	NULL
in	NULL
blood	NULL
flow	NULL
lead	NULL
to	NULL
acute	NULL
and	NULL
chronic	NULL
changes	NULL
in	NULL
oxygen	NULL
concentration	NULL
,	NULL
then	NULL
it	NULL
is	NULL
highly	NULL
probable	NULL
that	NULL
shuttling	NULL
between	NULL
different	NULL
oxygen	NULL
tensions	NULL
or	NULL
chronic	NULL
exposure	NULL
to	NULL
a	NULL
low	NULL
oxygen	NULL
tension	NULL
in	NULL
the	NULL
microenvironment	NULL
of	NULL
the	NULL
tumors	NULL
could	NULL
increase	NULL
the	NULL
activation	NULL
of	NULL
NF-	NULL
«	NULL
B	NULL
.	NULL

1425	NULL
Downloaded	NULL
from	NULL
cancerres.aacrjournals.org	NULL
on	NULL
May	NULL
10	NULL
,	NULL
2019	NULL
.	NULL

©	NULL
1994	NULL
American	NULL
Association	NULL
for	NULL
Cancer	NULL
Research	NULL
.	NULL

NF-	NULL
«	NULL
B	NULL
ACTIVATION	NULL
BY	NULL
HYPOXIA	NULL
In	NULL
this	NULL
paper	NULL
,	NULL
we	NULL
investigated	NULL
the	NULL
kinetics	NULL
of	NULL
IxBa	NULL
degradation	NULL
,	NULL
the	NULL
nuclear	NULL
translocation	NULL
of	NULL
p65	NULL
,	NULL
the	NULL
specific	NULL
DNA	NULL
binding	NULL
of	NULL
NF-	NULL
«	NULL
B	NULL
to	NULL
a	NULL
«	NULL
B	NULL
motif	NULL
,	NULL
and	NULL
the	NULL
transactivation	NULL
of	NULL
CAT	NULL
reporter	NULL
constructs	NULL
containing	NULL
«	NULL
B	NULL
binding	NULL
motifs	NULL
during	NULL
cellular	NULL
exposure	NULL
to	NULL
hypoxia	NULL
.	NULL

We	NULL
also	NULL
investigated	NULL
whether	NULL
the	NULL
signal	NULL
for	NULL
IxBa	NULL
degradation	NULL
,	NULL
NF-	NULL
«	NULL
B	NULL
binding	NULL
,	NULL
and	NULL
transactivation	NULL
is	NULL
mediated	NULL
through	NULL
protein	NULL
tyrosine	NULL
kinase	NULL
(	NULL
s	NULL
)	NULL
.	NULL

Our	NULL
data	NULL
suggest	NULL
that	NULL
the	NULL
activation	NULL
of	NULL
NF-	NULL
«	NULL
B	NULL
by	NULL
hypoxia	NULL
appears	NULL
to	NULL
represent	NULL
an	NULL
activation	NULL
pathway	NULL
different	NULL
than	NULL
that	NULL
caused	NULL
by	NULL
PMA	NULL
or	NULL
TNF	NULL
and	NULL
that	NULL
tyrosine	NULL
phosphorylation	NULL
of	NULL
I	NULL
«	NULL
Ba	NULL
is	NULL
an	NULL
important	NULL
proximal	NULL
step	NULL
in	NULL
the	NULL
dissociation	NULL
and	NULL
degradation	NULL
of	NULL
this	NULL
inhibitory	NULL
molecule	NULL
.	NULL

Materials	NULL
and	NULL
Methods	NULL
Cell	NULL
Culture	NULL
and	NULL
Treatments	NULL
.	NULL

Jurkat	NULL
T-cells	NULL
were	NULL
grown	NULL
in	NULL
RPMI	NULL
1640	NULL
supplemented	NULL
with	NULL
10	NULL
%	NULL
heat-inactivated	NULL
fetal	NULL
calf	NULL
serum	NULL
.	NULL

The	NULL
following	NULL
drug	NULL
concentrations	NULL
were	NULL
used	NULL
:	NULL
12-phorbol-13-myristate-acetate	NULL
(	NULL
PMA	NULL
,	NULL
1	NULL
um	NULL
;	NULL
Sigma	NULL
Chemical	NULL
Co.	NULL
,	NULL
St.	NULL
Louis	NULL
,	NULL
MO	NULL
)	NULL
,	NULL
TNF	NULL
(	NULL
10	NULL
ng/ml	NULL
,	NULL
kindly	NULL
provided	NULL
by	NULL
Dr.	NULL
J.	NULL
Elwell	NULL
,	NULL
Stanford	NULL
University	NULL
School	NULL
of	NULL
Medicine	NULL
)	NULL
,	NULL
staurosporine	NULL
(	NULL
1	NULL
um	NULL
,	NULL
Sigma	NULL
)	NULL
,	NULL
genistein	NULL
(	NULL
34-340	NULL
um	NULL
;	NULL
Gibco/BRL	NULL
,	NULL
Gaithersberg	NULL
,	NULL
MD	NULL
)	NULL
,	NULL
and	NULL
herbimycin	NULL
A	NULL
(	NULL
50-500	NULL
nm	NULL
;	NULL
Gibco/BRL	NULL
)	NULL
.	NULL

Hypoxia	NULL
Treatment	NULL
.	NULL

As	NULL
described	NULL
elsewhere	NULL
,	NULL
cells	NULL
were	NULL
treated	NULL
in	NULL
60-mm	NULL
glass	NULL
tissue	NULL
culture	NULL
dishes	NULL
(	NULL
Corning	NULL
)	NULL
with	NULL
notched	NULL
sides	NULL
to	NULL
allow	NULL
gas	NULL
exchange	NULL
between	NULL
the	NULL
medium	NULL
in	NULL
the	NULL
dish	NULL
and	NULL
the	NULL
environment	NULL
(	NULL
8	NULL
)	NULL
.	NULL

The	NULL
dishes	NULL
were	NULL
placed	NULL
in	NULL
specially	NULL
designed	NULL
aluminum	NULL
hypoxia	NULL
chambers	NULL
that	NULL
were	NULL
prewarmed	NULL
to	NULL
37°C	NULL
,	NULL
sealed	NULL
,	NULL
and	NULL
subjected	NULL
to	NULL
successive	NULL
rounds	NULL
of	NULL
evacuation	NULL
followed	NULL
by	NULL
flushing	NULL
with	NULL
95	NULL
%	NULL
N	NULL
;	NULL
/5	NULL
%	NULL
CO	NULL
;	NULL
while	NULL
being	NULL
slowly	NULL
agitated	NULL
on	NULL
a	NULL
reciprocating	NULL
shaker	NULL
.	NULL

The	NULL
chambers	NULL
were	NULL
then	NULL
placed	NULL
in	NULL
a	NULL
37°C	NULL
incubator	NULL
and	NULL
kept	NULL
on	NULL
a	NULL
reciprocating	NULL
shaker	NULL
for	NULL
the	NULL
duration	NULL
of	NULL
the	NULL
hypoxic	NULL
treatment	NULL
.	NULL

The	NULL
final	NULL
oxygen	NULL
concentration	NULL
in	NULL
the	NULL
media	NULL
after	NULL
5	NULL
cycles	NULL
was	NULL
reduced	NULL
to	NULL
0.02	NULL
%	NULL
.	NULL

Oxygen	NULL
concentration	NULL
was	NULL
measured	NULL
with	NULL
a	NULL
Clark-type	NULL
electrode	NULL
(	NULL
Controls	NULL
Katharobic	NULL
,	NULL
Edmonton	NULL
,	NULL
Alberta	NULL
,	NULL
Canada	NULL
)	NULL
.	NULL

In	NULL
the	NULL
combined	NULL
drug	NULL
and	NULL
hypoxia	NULL
treatments	NULL
,	NULL
cells	NULL
were	NULL
incubated	NULL
for	NULL
1	NULL
h	NULL
at	NULL
37°C	NULL
prior	NULL
to	NULL
the	NULL
initiation	NULL
of	NULL
hypoxia	NULL
.	NULL

Western	NULL
Blot	NULL
Analysis	NULL
.	NULL

Cells	NULL
were	NULL
lysed	NULL
in	NULL
a	NULL
buffer	NULL
containing	NULL
137	NULL
mm	NULL
NaCl	NULL
,	NULL
20	NULL
mm	NULL
Tris-HCI	NULL
(	NULL
pH	NULL
8.0	NULL
)	NULL
,	NULL
2	NULL
mm	NULL
EDTA	NULL
,	NULL
1	NULL
mm	NULL
phenylmethylsulfonyl	NULL
fluoride	NULL
,	NULL
1	NULL
mm	NULL
sodium	NULL
o-vanadate	NULL
,	NULL
100	NULL
nm	NULL
okadaic	NULL
acid	NULL
,	NULL
0.4	NULL
%	NULL
Nonidet	NULL
P-40	NULL
,	NULL
10	NULL
%	NULL
glycerol	NULL
,	NULL
10	NULL
ug/ml	NULL
leupeptin	NULL
,	NULL
1	NULL
ug/ml	NULL
aprotinin	NULL
,	NULL
and	NULL
1	NULL
mg/ml	NULL
pepstatin	NULL
by	NULL
sonication	NULL
with	NULL
4.5-s	NULL
pulses	NULL
of	NULL
75	NULL
W	NULL
while	NULL
on	NULL
ice	NULL
.	NULL

To	NULL
separate	NULL
nuclear	NULL
and	NULL
cytoplasmic	NULL
extracts	NULL
,	NULL
cells	NULL
were	NULL
lysed	NULL
in	NULL
the	NULL
above	NULL
mentioned	NULL
buffer	NULL
and	NULL
incubated	NULL
for	NULL
1	NULL
h	NULL
on	NULL
ice	NULL
.	NULL

Nuclei	NULL
were	NULL
pelleted	NULL
by	NULL
centrifugation	NULL
at	NULL
14,000	NULL
X	NULL
g	NULL
for	NULL
20	NULL
min	NULL
at	NULL
4°C	NULL
,	NULL
and	NULL
both	NULL
fractions	NULL
were	NULL
stored	NULL
at	NULL
-70°C	NULL
for	NULL
further	NULL
analysis	NULL
.	NULL

Protein	NULL
concentrations	NULL
of	NULL
each	NULL
sample	NULL
were	NULL
estimated	NULL
by	NULL
the	NULL
bicinchinonic	NULL
acid	NULL
method	NULL
(	NULL
Rockford	NULL
,	NULL
IL	NULL
)	NULL
.	NULL

Cell	NULL
extracts	NULL
were	NULL
mixed	NULL
with	NULL
2X	NULL
SDS	NULL
sample	NULL
buffer	NULL
[	NULL
62	NULL
mm	NULL
Tris	NULL
(	NULL
pH	NULL
6.8	NULL
)	NULL
-10	NULL
%	NULL
glycerol-2	NULL
%	NULL
SDS-5	NULL
%	NULL
B-mercaptoethanol-0.003	NULL
%	NULL
bromophenol	NULL
blue	NULL
]	NULL
,	NULL
heated	NULL
to	NULL
97°C	NULL
for	NULL
5	NULL
min	NULL
,	NULL
and	NULL
separated	NULL
by	NULL
SDS-polyacrylamide	NULL
gel	NULL
electrophoresis	NULL
.	NULL

After	NULL
electrophoresing	NULL
for	NULL
2	NULL
h	NULL
at	NULL
40	NULL
mA	NULL
in	NULL
a	NULL
10-12	NULL
%	NULL
polyacrylamide	NULL
gel	NULL
,	NULL
the	NULL
gel	NULL
was	NULL
transferred	NULL
onto	NULL
Hybond	NULL
ECL	NULL
(	NULL
Amersham	NULL
,	NULL
Arlington	NULL
Heights	NULL
,	NULL
IL	NULL
)	NULL
for	NULL
2	NULL
h	NULL
with	NULL
the	NULL
use	NULL
of	NULL
a	NULL
Bio-Rad	NULL
semidry	NULL
transfer	NULL
system	NULL
.	NULL

The	NULL
gels	NULL
were	NULL
then	NULL
stained	NULL
with	NULL
0.15	NULL
%	NULL
Coomassie	NULL
blue	NULL
to	NULL
ensure	NULL
a	NULL
uniform	NULL
transfer	NULL
.	NULL

The	NULL
membranes	NULL
were	NULL
then	NULL
probed	NULL
with	NULL
either	NULL
I	NULL
«	NULL
Ba	NULL
antibody	NULL
(	NULL
kindly	NULL
provided	NULL
by	NULL
Dr.	NULL
Warner	NULL
Greene	NULL
,	NULL
University	NULL
of	NULL
California	NULL
at	NULL
San	NULL
Francisco	NULL
)	NULL
,	NULL
p65	NULL
antibody	NULL
(	NULL
Santa	NULL
Cruz	NULL
Biotechnology	NULL
,	NULL
Santa	NULL
Cruz	NULL
,	NULL
CA	NULL
)	NULL
,	NULL
or	NULL
anti-phosphotyrosine	NULL
antibody	NULL
(	NULL
UBI	NULL
Biotechnology	NULL
,	NULL
Lake	NULL
Placid	NULL
,	NULL
NY	NULL
)	NULL
.	NULL

The	NULL
membranes	NULL
were	NULL
than	NULL
autoradiographed	NULL
utilizing	NULL
enhanced	NULL
chemillumines-cence	NULL
according	NULL
to	NULL
the	NULL
manufacturer	NULL
's	NULL
protocol	NULL
(	NULL
Amersham	NULL
)	NULL
.	NULL

Gel	NULL
Mobility	NULL
Shift	NULL
Assays	NULL
.	NULL

Nuclear	NULL
extracts	NULL
were	NULL
prepared	NULL
by	NULL
lysing	NULL
the	NULL
cells	NULL
in	NULL
10	NULL
mu	NULL
Hepes	NULL
(	NULL
pH	NULL
7.9	NULL
)	NULL
-10	NULL
mu	NULL
KCI-1	NULL
mu	NULL
PMSF-1.5	NULL
mm	NULL
MgCl	NULL
;	NULL
-1	NULL
mm	NULL
DTT-2	NULL
ug/ml	NULL
leupeptin-2	NULL
ug/ml	NULL
aprotinin	NULL
.	NULL

Cells	NULL
were	NULL
then	NULL
homogenized	NULL
and	NULL
nuclei	NULL
were	NULL
collected	NULL
by	NULL
centrifugation	NULL
(	NULL
3000	NULL
rpm	NULL
,	NULL
5	NULL
min	NULL
)	NULL
.	NULL

The	NULL
nuclear	NULL
pellet	NULL
was	NULL
then	NULL
resuspended	NULL
in	NULL
25	NULL
mm	NULL
Hepes	NULL
(	NULL
pH	NULL
7.9	NULL
)	NULL
-0.44	NULL
m	NULL
KCI-5	NULL
mm	NULL
MgCl	NULL
,	NULL
-0.1	NULL
mm	NULL
EDTA	NULL
,	NULL
1	NULL
mm	NULL
phenylmethylIsulfonyl	NULL
fluoride-2	NULL
mm	NULL
DTT-20	NULL
%	NULL
glycerol	NULL
.	NULL

The	NULL
supernatant	NULL
was	NULL
then	NULL
collected	NULL
after	NULL
centrifugation	NULL
(	NULL
31,000	NULL
rpm	NULL
,	NULL
10	NULL
min	NULL
)	NULL
.	NULL

A	NULL
radiolabeled	NULL
oligonucleotide	NULL
with	NULL
the	NULL
sequence	NULL
5'-AGTTGAGGGGACTTTC-CCAGGC-3	NULL
'	NULL
was	NULL
used	NULL
in	NULL
all	NULL
of	NULL
the	NULL
NF-	NULL
«	NULL
B	NULL
binding	NULL
studies	NULL
.	NULL

Six	NULL
pug	NULL
of	NULL
nuclear	NULL
extract	NULL
(	NULL
as	NULL
determined	NULL
by	NULL
the	NULL
bicinchinonic	NULL
assay	NULL
method	NULL
)	NULL
was	NULL
used	NULL
in	NULL
each	NULL
binding	NULL
reaction	NULL
.	NULL

The	NULL
binding	NULL
reactions	NULL
were	NULL
carried	NULL
out	NULL
at	NULL
room	NULL
temperature	NULL
for	NULL
20	NULL
min	NULL
in	NULL
a	NULL
buffer	NULL
containing	NULL
500	NULL
ng	NULL
sonicated	NULL
salmon	NULL
sperm	NULL
,	NULL
10	NULL
mm	NULL
Hepes	NULL
(	NULL
pH	NULL
7.8	NULL
)	NULL
,	NULL
5	NULL
mm	NULL
MgCl	NULL
;	NULL
,	NULL
60	NULL
mm	NULL
KCI	NULL
,	NULL
0.5	NULL
mm	NULL
DTT	NULL
,	NULL
1	NULL
mm	NULL
spermidine	NULL
,	NULL
and	NULL
10	NULL
%	NULL
glycerol	NULL
in	NULL
a	NULL
final	NULL
volume	NULL
of	NULL
20	NULL
ul	NULL
.	NULL

Competitors	NULL
were	NULL
added	NULL
in	NULL
a	NULL
100-fold	NULL
molar	NULL
excess	NULL
to	NULL
demonstrate	NULL
the	NULL
specificity	NULL
of	NULL
the	NULL
binding	NULL
reaction	NULL
.	NULL

After	NULL
electrophoresis	NULL
on	NULL
a	NULL
6	NULL
%	NULL
polyacrylamide	NULL
gel	NULL
(	NULL
140	NULL
V	NULL
,	NULL
2.5	NULL
h	NULL
)	NULL
,	NULL
the	NULL
gel	NULL
was	NULL
dried	NULL
onto	NULL
Whatman	NULL
filter	NULL
paper	NULL
and	NULL
visualized	NULL
by	NULL
autoradiography	NULL
(	NULL
Hyperfilm	NULL
;	NULL
Amersham	NULL
)	NULL
.	NULL

Transfection	NULL
Studies	NULL
.	NULL

Plasmid	NULL
(	NULL
10	NULL
pg	NULL
)	NULL
DNA	NULL
was	NULL
electroporated	NULL
(	NULL
Gene	NULL
Pulser	NULL
;	NULL
Bio-Rad	NULL
)	NULL
into	NULL
1	NULL
X	NULL
10	NULL
``	NULL
Jurkat	NULL
T-cells	NULL
in	NULL
a	NULL
volume	NULL
of	NULL
200	NULL
pl	NULL
.	NULL

Cells	NULL
were	NULL
electroporated	NULL
in	NULL
media	NULL
at	NULL
240	NULL
V	NULL
with	NULL
a	NULL
capacitance	NULL
of	NULL
960	NULL
uF	NULL
and	NULL
then	NULL
incubated	NULL
on	NULL
ice	NULL
for	NULL
10	NULL
min	NULL
after	NULL
electroporation	NULL
before	NULL
being	NULL
plated	NULL
into	NULL
glass	NULL
dishes	NULL
for	NULL
hypoxia	NULL
treatment	NULL
.	NULL

From	NULL
24	NULL
to	NULL
36	NULL
h	NULL
after	NULL
transfection	NULL
,	NULL
cells	NULL
were	NULL
exposed	NULL
to	NULL
hypoxia	NULL
for	NULL
5	NULL
h	NULL
and	NULL
immediately	NULL
lysed	NULL
3	NULL
h	NULL
later	NULL
for	NULL
CAT	NULL
activity	NULL
analysis	NULL
.	NULL

CAT	NULL
activity	NULL
was	NULL
determined	NULL
either	NULL
by	NULL
thin	NULL
layer	NULL
chromatography	NULL
(	NULL
33	NULL
)	NULL
as	NULL
described	NULL
previously	NULL
(	NULL
5	NULL
)	NULL
or	NULL
by	NULL
enzyme	NULL
linked	NULL
immunosorbent	NULL
assay	NULL
according	NULL
to	NULL
the	NULL
manufacturer	NULL
's	NULL
protocol	NULL
(	NULL
Boehringer	NULL
Mannheim	NULL
,	NULL
Indianapolis	NULL
,	NULL
IN	NULL
)	NULL
.	NULL

To	NULL
eliminate	NULL
differences	NULL
in	NULL
transfection	NULL
efficiencies	NULL
,	NULL
transfected	NULL
cells	NULL
were	NULL
pooled	NULL
together	NULL
(	NULL
for	NULL
24	NULL
h	NULL
following	NULL
electroporation	NULL
)	NULL
before	NULL
being	NULL
split	NULL
into	NULL
separate	NULL
groups	NULL
for	NULL
treatments	NULL
.	NULL

All	NULL
transfection	NULL
experiments	NULL
were	NULL
performed	NULL
3-5	NULL
times	NULL
.	NULL

Little	NULL
fluctuation	NULL
was	NULL
seen	NULL
among	NULL
experiments	NULL
.	NULL

Raf301	NULL
was	NULL
kindly	NULL
provided	NULL
by	NULL
Dr.	NULL
P.	NULL
Stambrook	NULL
,	NULL
University	NULL
of	NULL
Cinncinati	NULL
School	NULL
of	NULL
Medicine	NULL
.	NULL

Immunoprecipitation	NULL
.	NULL

Protein	NULL
A	NULL
beads	NULL
were	NULL
allowed	NULL
to	NULL
swell	NULL
for	NULL
1	NULL
h	NULL
at	NULL
room	NULL
temperature	NULL
in	NULL
phosphate	NULL
buffer	NULL
(	NULL
0.14	NULL
m	NULL
Na	NULL
;	NULL
HPO	NULL
,	NULL
-12H	NULL
,	NULL
0-0.01	NULL
%	NULL
NaN	NULL
)	NULL
,	NULL
pH	NULL
9.0	NULL
)	NULL
.	NULL

The	NULL
beads	NULL
were	NULL
then	NULL
washed	NULL
3	NULL
times	NULL
with	NULL
water	NULL
and	NULL
resuspended	NULL
in	NULL
a	NULL
50	NULL
%	NULL
phosphate	NULL
buffer	NULL
solution	NULL
.	NULL

The	NULL
antibody	NULL
was	NULL
allowed	NULL
to	NULL
bind	NULL
to	NULL
the	NULL
beads	NULL
overnight	NULL
(	NULL
5	NULL
pl	NULL
of	NULL
antibody	NULL
,	NULL
20	NULL
ul	NULL
of	NULL
protein	NULL
A	NULL
solution	NULL
,	NULL
and	NULL
400	NULL
pl	NULL
of	NULL
1	NULL
%	NULL
bovine	NULL
serum	NULL
albumin	NULL
in	NULL
phosphate	NULL
buffer	NULL
)	NULL
while	NULL
being	NULL
turned	NULL
at	NULL
4°C	NULL
.	NULL

The	NULL
beads	NULL
were	NULL
then	NULL
pelleted	NULL
and	NULL
washed	NULL
twice	NULL
with	NULL
phosphate	NULL
buffer	NULL
.	NULL

Cell	NULL
extract	NULL
was	NULL
then	NULL
added	NULL
to	NULL
the	NULL
beads	NULL
and	NULL
turned	NULL
overnight	NULL
at	NULL
4°C	NULL
.	NULL

The	NULL
beads	NULL
were	NULL
then	NULL
pelleted	NULL
and	NULL
washed	NULL
twice	NULL
with	NULL
phosphate	NULL
buffer	NULL
before	NULL
being	NULL
mixed	NULL
with	NULL
2X	NULL
SDS	NULL
sample	NULL
buffer	NULL
and	NULL
heated	NULL
to	NULL
97°C	NULL
.	NULL

After	NULL
centrifugation	NULL
to	NULL
remove	NULL
the	NULL
beads	NULL
,	NULL
the	NULL
supernatants	NULL
with	NULL
the	NULL
immunoprecipitated	NULL
proteins	NULL
were	NULL
electrophoresed	NULL
on	NULL
a	NULL
12	NULL
%	NULL
SDS-polyacrylamide	NULL
gel	NULL
and	NULL
visualized	NULL
by	NULL
Western	NULL
blotting	NULL
as	NULL
described	NULL
above	NULL
.	NULL

Results	NULL
and	NULL
Discussion	NULL
To	NULL
assess	NULL
the	NULL
dynamics	NULL
of	NULL
IxBa	NULL
and	NULL
NF-KB	NULL
interactions	NULL
under	NULL
hypoxia	NULL
,	NULL
cells	NULL
were	NULL
exposed	NULL
to	NULL
varying	NULL
durations	NULL
of	NULL
hypoxia	NULL
(	NULL
0.02	NULL
%	NULL
)	NULL
and	NULL
subcellular	NULL
fractions	NULL
were	NULL
assayed	NULL
by	NULL
Western	NULL
blot	NULL
and	NULL
gel	NULL
mobility	NULL
shift	NULL
analysis	NULL
for	NULL
IxBa	NULL
degradation	NULL
(	NULL
Fig	NULL
.	NULL

14	NULL
)	NULL
,	NULL
p65	NULL
nuclear	NULL
translocation	NULL
(	NULL
Fig	NULL
.	NULL

1B	NULL
)	NULL
,	NULL
and	NULL
NF-KB	NULL
binding	NULL
(	NULL
Fig	NULL
.	NULL

1C	NULL
)	NULL
.	NULL

Fig	NULL
.	NULL

14	NULL
shows	NULL
that	NULL
IxBa	NULL
,	NULL
a	NULL
37,000	NULL
M	NULL
,	NULL
cytoplasmic	NULL
protein	NULL
,	NULL
disappears	NULL
within	NULL
1-3	NULL
h	NULL
after	NULL
exposure	NULL
to	NULL
0.02	NULL
%	NULL
oxygen	NULL
and	NULL
reappears	NULL
after	NULL
4	NULL
h.	NULL
The	NULL
antibody	NULL
used	NULL
to	NULL
probe	NULL
this	NULL
immunoblot	NULL
was	NULL
raised	NULL
against	NULL
the	NULL
COOH	NULL
terminus	NULL
of	NULL
IxBa	NULL
(	NULL
amino	NULL
acids	NULL
289-317	NULL
)	NULL
and	NULL
has	NULL
been	NULL
shown	NULL
to	NULL
recognize	NULL
authentic	NULL
IxBa	NULL
protein	NULL
(	NULL
34	NULL
)	NULL
.	NULL

The	NULL
kinetics	NULL
for	NULL
the	NULL
disappearance	NULL
of	NULL
IxBa	NULL
after	NULL
hypoxia	NULL
treatment	NULL
was	NULL
slower	NULL
than	NULL
that	NULL
reported	NULL
by	NULL
Sun	NULL
et	NULL
al	NULL
.	NULL

(	NULL
34	NULL
)	NULL
after	NULL
cellular	NULL
exposure	NULL
to	NULL
PMA	NULL
or	NULL
TNFa	NULL
.	NULL

Because	NULL
it	NULL
has	NULL
been	NULL
shown	NULL
previously	NULL
that	NULL
NF-	NULL
«	NULL
B	NULL
controls	NULL
the	NULL
expression	NULL
(	NULL
resynthesis	NULL
of	NULL
IxBa	NULL
after	NULL
degradation	NULL
)	NULL
of	NULL
the	NULL
inhibitor	NULL
IxBa	NULL
by	NULL
an	NULL
inducible	NULL
autoregulatory	NULL
pathway	NULL
,	NULL
we	NULL
found	NULL
that	NULL
the	NULL
resynthesis	NULL
of	NULL
IxBa	NULL
under	NULL
hypoxic	NULL
conditions	NULL
(	NULL
4-5	NULL
h	NULL
)	NULL
is	NULL
also	NULL
slower	NULL
than	NULL
that	NULL
following	NULL
PMA	NULL
or	NULL
TNFa	NULL
treatment	NULL
(	NULL
Fig	NULL
.	NULL

14	NULL
)	NULL
.	NULL

However	NULL
,	NULL
as	NULL
has	NULL
been	NULL
found	NULL
with	NULL
other	NULL
agonists	NULL
of	NULL
IxBa	NULL
degradation	NULL
,	NULL
the	NULL
resynthesis	NULL
of	NULL
IxBa	NULL
during	NULL
hypoxia	NULL
is	NULL
also	NULL
inhibited	NULL
by	NULL
treatment	NULL
of	NULL
cells	NULL
with	NULL
cycloheximide	NULL
(	NULL
data	NULL
not	NULL
shown	NULL
)	NULL
.	NULL

The	NULL
predominant	NULL
protein	NULL
complex	NULL
of	NULL
NF-KB	NULL
in	NULL
the	NULL
cell	NULL
is	NULL
composed	NULL
of	NULL
homo-	NULL
or	NULL
heterodimers	NULL
which	NULL
form	NULL
between	NULL
proteins	NULL
with	NULL
molecular	NULL
weights	NULL
of	NULL
50,000	NULL
(	NULL
p50	NULL
subunit	NULL
)	NULL
and	NULL
65,000	NULL
(	NULL
p65	NULL
subunit	NULL
)	NULL
molecular	NULL
weight	NULL
.	NULL

To	NULL
confirm	NULL
that	NULL
IxBa	NULL
dissociation	NULL
by	NULL
hypoxia	NULL
results	NULL
in	NULL
p65	NULL
translocation	NULL
from	NULL
the	NULL
cytoplasm	NULL
to	NULL
the	NULL
nucleus	NULL
,	NULL
nuclear	NULL
extracts	NULL
were	NULL
assayed	NULL
for	NULL
an	NULL
increase	NULL
in	NULL
p65	NULL
protein	NULL
levels	NULL
by	NULL
Western	NULL
blotting	NULL
(	NULL
Fig	NULL
.	NULL

1B	NULL
)	NULL
.	NULL

The	NULL
kinetics	NULL
of	NULL
p65	NULL
increasing	NULL
in	NULL
the	NULL
nucleus	NULL
mirrors	NULL
the	NULL
kinetics	NULL
for	NULL
IxBa	NULL
disappearance	NULL
in	NULL
the	NULL
cytoplasm	NULL
.	NULL

A	NULL
further	NULL
indication	NULL
of	NULL
NF-	NULL
«	NULL
B	NULL
activation	NULL
by	NULL
hypoxia	NULL
is	NULL
demonstrated	NULL
by	NULL
its	NULL
binding	NULL
to	NULL
a	NULL
32P-labeled	NULL
palindromic	NULL
«	NULL
B	NULL
probe	NULL
.	NULL

Fig	NULL
.	NULL

1C	NULL
shows	NULL
that	NULL
NF-	NULL
«	NULL
B	NULL
binding	NULL
increases	NULL
during	NULL
exposure	NULL
to	NULL
hypoxia	NULL
.	NULL

This	NULL
binding	NULL
is	NULL
not	NULL
affected	NULL
by	NULL
1426	NULL
Downloaded	NULL
from	NULL
cancerres.aacrjournals.org	NULL
on	NULL
May	NULL
10	NULL
,	NULL
2019	NULL
.	NULL

©	NULL
1994	NULL
American	NULL
Association	NULL
for	NULL
Cancer	NULL
Research	NULL
.	NULL

NF-kB	NULL
ACTIVATION	NULL
BY	NULL
HYPOXIA	NULL
Time	NULL
under	NULL
Hypoxia	NULL
(	NULL
hr	NULL
)	NULL
air	NULL
_	NULL
1	NULL
2	NULL
3	NULL
4	NULL
§	NULL
A	NULL
_-	NULL
IxBa	NULL
.-	NULL
»	NULL
#	NULL
Rfrzmak	NULL
:	NULL
Sik	NULL
Time	NULL
under	NULL
Hypoxia	NULL
(	NULL
hr	NULL
)	NULL
alr	NULL
O10	NULL
20030	NULL
4	NULL
0	NULL
5	NULL
6	NULL
0	NULL
p65	NULL
-	NULL
ae	NULL
Time	NULL
undgr	NULL
38	NULL
Hypoxia	NULL
(	NULL
hr	NULL
)	NULL
“	NULL
ﬁx	NULL
“	NULL
?	NULL

M	NULL
alr	NULL
10	NULL
20	NULL
3	NULL
4	NULL
5	NULL
C	NULL
NF-	NULL
«	NULL
B	NULL
-	NULL
«	NULL
»	NULL
U	NULL
»	NULL
a	NULL
>	NULL
Fig	NULL
.	NULL

1	NULL
.	NULL

Activation	NULL
of	NULL
NF-xB	NULL
by	NULL
low	NULL
oxygen	NULL
conditions	NULL
.	NULL

A	NULL
,	NULL
kinetics	NULL
of	NULL
degradation	NULL
and	NULL
resynthesis	NULL
of	NULL
IxBa	NULL
during	NULL
exposure	NULL
of	NULL
Jurkat	NULL
T	NULL
cells	NULL
to	NULL
0.02	NULL
%	NULL
oxygen	NULL
as	NULL
detected	NULL
by	NULL
immunoblot	NULL
analysis	NULL
with	NULL
peptide	NULL
antiserum	NULL
to	NULL
the	NULL
COOH	NULL
terminus	NULL
of	NULL
IxBa	NULL
;	NULL
B	NULL
,	NULL
kinetics	NULL
of	NULL
p65	NULL
protein	NULL
accumulation	NULL
in	NULL
the	NULL
nucleus	NULL
as	NULL
a	NULL
function	NULL
of	NULL
time	NULL
under	NULL
hypoxia	NULL
(	NULL
yp	NULL
)	NULL
as	NULL
detected	NULL
by	NULL
probing	NULL
immunoblots	NULL
with	NULL
anti-p65	NULL
antibody	NULL
;	NULL
C	NULL
,	NULL
kinetics	NULL
of	NULL
NF-	NULL
«	NULL
B	NULL
binding	NULL
in	NULL
nuclear	NULL
extracts	NULL
of	NULL
hypoxia-treated	NULL
cells	NULL
as	NULL
a	NULL
function	NULL
of	NULL
time	NULL
.	NULL

cycloheximide	NULL
(	NULL
data	NULL
not	NULL
shown	NULL
)	NULL
and	NULL
is	NULL
competed	NULL
out	NULL
by	NULL
a	NULL
100-fold	NULL
molar	NULL
excess	NULL
of	NULL
unlabeled	NULL
«	NULL
B	NULL
probe	NULL
(	NULL
Fig	NULL
.	NULL

1C	NULL
)	NULL
.	NULL

To	NULL
examine	NULL
whether	NULL
the	NULL
increase	NULL
in	NULL
NF-	NULL
«	NULL
B	NULL
binding	NULL
induced	NULL
by	NULL
hypoxia	NULL
was	NULL
functionally	NULL
able	NULL
to	NULL
transactivate	NULL
genes	NULL
that	NULL
possess	NULL
kB	NULL
binding	NULL
sites	NULL
,	NULL
we	NULL
tested	NULL
reporter	NULL
gene	NULL
plasmids	NULL
possessing	NULL
the	NULL
full	NULL
length	NULL
HIV	NULL
long	NULL
terminal	NULL
repeat	NULL
promoter	NULL
(	NULL
35	NULL
)	NULL
and	NULL
the	NULL
same	NULL
HIV	NULL
long	NULL
terminal	NULL
repeat	NULL
with	NULL
two	NULL
NF-	NULL
«	NULL
B	NULL
mutations	NULL
(	NULL
PkKBM	NULL
)	NULL
(	NULL
36	NULL
)	NULL
.	NULL

Jurkat	NULL
T-cells	NULL
were	NULL
transiently	NULL
transfected	NULL
with	NULL
either	NULL
construct	NULL
,	NULL
exposed	NULL
to	NULL
0.02	NULL
%	NULL
oxygen	NULL
for	NULL
5	NULL
h	NULL
,	NULL
and	NULL
then	NULL
assayed	NULL
for	NULL
CAT	NULL
activity	NULL
.	NULL

To	NULL
minimize	NULL
variations	NULL
in	NULL
plasmid	NULL
transfection	NULL
efficiencies	NULL
,	NULL
transfectants	NULL
were	NULL
pooled	NULL
for	NULL
24	NULL
h	NULL
after	NULL
transfection	NULL
,	NULL
before	NULL
separating	NULL
them	NULL
into	NULL
various	NULL
treatment	NULL
groups	NULL
.	NULL

The	NULL
data	NULL
shown	NULL
represent	NULL
the	NULL
mean	NULL
+	NULL
SEM	NULL
of	NULL
3-5	NULL
independent	NULL
experiments	NULL
.	NULL

Fig	NULL
.	NULL

24	NULL
shows	NULL
that	NULL
cells	NULL
transfected	NULL
with	NULL
HIV-CAT	NULL
increased	NULL
their	NULL
CAT	NULL
activity	NULL
3-fold	NULL
after	NULL
a	NULL
5-h	NULL
exposure	NULL
to	NULL
hypoxia	NULL
.	NULL

When	NULL
the	NULL
HIV-CAT	NULL
plasmid	NULL
construct	NULL
containing	NULL
2	NULL
mutated	NULL
«	NULL
B	NULL
sites	NULL
(	NULL
PKBM	NULL
)	NULL
was	NULL
transfected	NULL
,	NULL
no	NULL
transactivation	NULL
by	NULL
hypoxia	NULL
was	NULL
observed	NULL
(	NULL
Fig	NULL
.	NULL

24	NULL
)	NULL
.	NULL

Thus	NULL
,	NULL
hypoxia	NULL
can	NULL
activate	NULL
NF-KB	NULL
to	NULL
bind	NULL
DNA	NULL
in	NULL
a	NULL
sequence	NULL
specific	NULL
manner	NULL
and	NULL
enhance	NULL
transactivation	NULL
of	NULL
genes	NULL
which	NULL
possess	NULL
«	NULL
B-binding	NULL
sites	NULL
.	NULL

To	NULL
this	NULL
point	NULL
,	NULL
we	NULL
have	NULL
presented	NULL
evidence	NULL
that	NULL
hypoxia	NULL
causes	NULL
the	NULL
degradation	NULL
of	NULL
IxBa	NULL
and	NULL
the	NULL
nuclear	NULL
translocation	NULL
of	NULL
NF-	NULL
«	NULL
B	NULL
and	NULL
enhances	NULL
the	NULL
transcriptional	NULL
activation	NULL
of	NULL
reporter	NULL
constructs	NULL
containing	NULL
«	NULL
B-binding	NULL
sites	NULL
.	NULL

Since	NULL
previous	NULL
studies	NULL
have	NULL
demonstrated	NULL
that	NULL
the	NULL
activation	NULL
of	NULL
NF-	NULL
«	NULL
B	NULL
by	NULL
certain	NULL
agonists	NULL
can	NULL
be	NULL
inhibited	NULL
by	NULL
the	NULL
use	NULL
of	NULL
protein	NULL
kinase	NULL
inhibitors	NULL
(	NULL
37	NULL
,	NULL
38	NULL
)	NULL
,	NULL
cells	NULL
were	NULL
exposed	NULL
simultaneously	NULL
to	NULL
0.02	NULL
%	NULL
oxygen	NULL
in	NULL
the	NULL
presence	NULL
or	NULL
absence	NULL
of	NULL
protein	NULL
kinase	NULL
inhibitors	NULL
.	NULL

The	NULL
results	NULL
from	NULL
Fig	NULL
.	NULL

2B	NULL
show	NULL
that	NULL
NF-	NULL
«	NULL
B	NULL
induction	NULL
by	NULL
hypoxia	NULL
was	NULL
inhibited	NULL
by	NULL
pretreatment	NULL
of	NULL
cells	NULL
with	NULL
the	NULL
general	NULL
protein	NULL
kinase	NULL
inhibitor	NULL
staurosporine	NULL
,	NULL
or	NULL
the	NULL
tyrosine	NULL
kinase	NULL
inhibitors	NULL
herbimycin	NULL
A	NULL
and	NULL
genistein	NULL
,	NULL
suggesting	NULL
that	NULL
tyrosine	NULL
kinases	NULL
may	NULL
be	NULL
involved	NULL
in	NULL
NF-KB	NULL
activation	NULL
(	NULL
39	NULL
)	NULL
.	NULL

Furthermore	NULL
,	NULL
the	NULL
induction	NULL
of	NULL
NF-	NULL
«	NULL
B	NULL
seemed	NULL
to	NULL
be	NULL
induced	NULL
by	NULL
hypoxia	NULL
itself	NULL
and	NULL
not	NULL
reoxygenation	NULL
inasmuch	NULL
as	NULL
these	NULL
same	NULL
inhibitors	NULL
were	NULL
only	NULL
able	NULL
to	NULL
inhibit	NULL
transac-	NULL
tivation	NULL
of	NULL
HIV-CAT	NULL
if	NULL
they	NULL
were	NULL
added	NULL
after	NULL
hypoxia	NULL
(	NULL
using	NULL
a	NULL
special	NULL
hypoxia	NULL
glove	NULL
box	NULL
)	NULL
,	NULL
but	NULL
before	NULL
reoxygenation	NULL
.	NULL

To	NULL
further	NULL
explore	NULL
where	NULL
in	NULL
the	NULL
pathway	NULL
these	NULL
protein	NULL
kinase	NULL
inhibitors	NULL
were	NULL
working	NULL
,	NULL
we	NULL
analyzed	NULL
the	NULL
effect	NULL
of	NULL
these	NULL
same	NULL
protein	NULL
kinase	NULL
inhibitors	NULL
on	NULL
IxBa	NULL
degradation	NULL
and	NULL
NF-KB	NULL
activation	NULL
.	NULL

Fig	NULL
.	NULL

3	NULL
is	NULL
a	NULL
series	NULL
of	NULL
Western	NULL
blots	NULL
and	NULL
gel	NULL
mobility	NULL
shift	NULL
assays	NULL
showing	NULL
that	NULL
hypoxia-induced	NULL
IxBa	NULL
degradation	NULL
and	NULL
NF-kB	NULL
binding	NULL
can	NULL
be	NULL
blocked	NULL
by	NULL
pretreating	NULL
cells	NULL
with	NULL
these	NULL
same	NULL
protein	NULL
kinase	NULL
inhibitors	NULL
.	NULL

Although	NULL
staurosporine	NULL
inhibits	NULL
serine/threonine	NULL
kinases	NULL
,	NULL
it	NULL
also	NULL
inhibits	NULL
tyrosine	NULL
kinase	NULL
activity	NULL
at	NULL
the	NULL
concentrations	NULL
used	NULL
in	NULL
these	NULL
studies	NULL
(	NULL
39	NULL
)	NULL
.	NULL

In	NULL
contrast	NULL
,	NULL
genistein	NULL
and	NULL
herbimycin	NULL
A	NULL
are	NULL
more	NULL
specific	NULL
tyrosine	NULL
kinase	NULL
inhibitors	NULL
(	NULL
39	NULL
)	NULL
.	NULL

These	NULL
results	NULL
suggest	NULL
that	NULL
tyrosine	NULL
kinase	NULL
(	NULL
s	NULL
)	NULL
play	NULL
an	NULL
important	NULL
role	NULL
in	NULL
the	NULL
signaling	NULL
pathway	NULL
leading	NULL
to	NULL
NF-KB	NULL
activation	NULL
by	NULL
hypoxia	NULL
.	NULL

Recently	NULL
,	NULL
Beg	NULL
et	NULL
al	NULL
.	NULL

(	NULL
31	NULL
)	NULL
have	NULL
demonstrated	NULL
the	NULL
in	NULL
vivo	NULL
phosphorylation	NULL
of	NULL
IxBa	NULL
after	NULL
TNFa	NULL
treatment	NULL
of	NULL
cells	NULL
.	NULL

From	NULL
the	NULL
results	NULL
de	NULL
A	NULL
us	NULL
Induction	NULL
HIV-CAT	NULL
PKBM	NULL
Treatment	NULL
Induction	NULL
herb	NULL
stauro	NULL
gen	NULL
air	NULL
hyp	NULL
Treatment	NULL
Fig	NULL
.	NULL

2	NULL
.	NULL

Transactivation	NULL
activity	NULL
of	NULL
hypoxia-induced	NULL
NF-	NULL
«	NULL
B	NULL
activity	NULL
.	NULL

A	NULL
,	NULL
induction	NULL
of	NULL
CAT	NULL
activity	NULL
by	NULL
hypoxia	NULL
in	NULL
Jurkat	NULL
T-cells	NULL
that	NULL
were	NULL
transfected	NULL
with	NULL
the	NULL
HIV-CAT	NULL
plasmid	NULL
which	NULL
contains	NULL
two	NULL
functional	NULL
NF-B	NULL
binding	NULL
sites	NULL
or	NULL
with	NULL
the	NULL
PKBM	NULL
plasmid	NULL
which	NULL
is	NULL
identical	NULL
to	NULL
HIV-CAT	NULL
except	NULL
its	NULL
two	NULL
NF-xB	NULL
binding	NULL
sites	NULL
have	NULL
been	NULL
mutated	NULL
.	NULL

B	NULL
,	NULL
effect	NULL
of	NULL
pretreating	NULL
HIV-CAT	NULL
transfectants	NULL
with	NULL
the	NULL
protein	NULL
kinase	NULL
inhibitors	NULL
staurosporine	NULL
(	NULL
stauro	NULL
)	NULL
,	NULL
genistein	NULL
(	NULL
gen	NULL
)	NULL
,	NULL
and	NULL
herbimycin	NULL
A	NULL
(	NULL
herb	NULL
)	NULL
before	NULL
exposure	NULL
to	NULL
hypoxia	NULL
.	NULL

Bars	NULL
,	NULL
SEM	NULL
.	NULL

1427	NULL
Downloaded	NULL
from	NULL
cancerres.aacrjournals.org	NULL
on	NULL
May	NULL
10	NULL
,	NULL
2019	NULL
.	NULL

©	NULL
1994	NULL
American	NULL
Association	NULL
for	NULL
Cancer	NULL
Research	NULL
.	NULL

NF-	NULL
«	NULL
B	NULL
ACTIVATION	NULL
BY	NULL
HYPOXIA	NULL
Time	NULL
under	NULL
tated	NULL
IxBa	NULL
from	NULL
cells	NULL
that	NULL
were	NULL
exposed	NULL
for	NULL
varying	NULL
times	NULL
to	NULL
hypoxia	NULL
,	NULL
Hypoxia	NULL
(	NULL
hr	NULL
)	NULL
electrophoresed	NULL
the	NULL
immunoprecipitates	NULL
on	NULL
a	NULL
12	NULL
%	NULL
SDS	NULL
polyacryl-	NULL
3	NULL
amide	NULL
gel	NULL
,	NULL
and	NULL
transferred	NULL
them	NULL
to	NULL
Hybond	NULL
nitrocellulose	NULL
for	NULL
immuno-blotting	NULL
.	NULL

These	NULL
membranes	NULL
were	NULL
then	NULL
probed	NULL
with	NULL
antibody	NULL
that	NULL
specifically	NULL
recognizes	NULL
phosphorylated	NULL
tyrosine	NULL
residues	NULL
(	NULL
40	NULL
,	NULL
41	NULL
)	NULL
.	NULL

We	NULL
consistently	NULL
found	NULL
that	NULL
IxBa	NULL
exhibited	NULL
increased	NULL
tyrosine	NULL
phosphorylation	NULL
as	NULL
a	NULL
function	NULL
of	NULL
time	NULL
exposed	NULL
to	NULL
hypoxia	NULL
(	NULL
Fig	NULL
.	NULL

4C	NULL
)	NULL
.	NULL

This	NULL
increase	NULL
in	NULL
tyrosine	NULL
phosphorylation	NULL
mirrored	NULL
the	NULL
kinetics	NULL
of	NULL
IkBa	NULL
degradation	NULL
in	NULL
the	NULL
cytoplasm	NULL
.	NULL

Blocking	NULL
tyrosine	NULL
phosphorylation	NULL
of	NULL
IxBa	NULL
with	NULL
herbimycin	NULL
A	NULL
(	NULL
Fig	NULL
.	NULL

4C	NULL
,	NULL
Lane	NULL
5	NULL
)	NULL
inhibited	NULL
both	NULL
the	NULL
degra-x	NULL
go	NULL
x	NULL
8	NULL
?	NULL

dation	NULL
of	NULL
IxBa	NULL
and	NULL
NF-	NULL
«	NULL
B	NULL
binding	NULL
(	NULL
Fig	NULL
.	NULL

3	NULL
)	NULL
.	NULL

In	NULL
contrast	NULL
to	NULL
hypoxia-Re	NULL
}	NULL
R	NULL
}	NULL
Q	NULL
treated	NULL
cells	NULL
,	NULL
cells	NULL
treated	NULL
with	NULL
PMA	NULL
or	NULL
TNF	NULL
exhibited	NULL
weak	NULL
cross-D	NULL
‘	NULL
bé	NULL
é	NULL
$	NULL
30	NULL
$	NULL
Qwé	NULL
reactivity	NULL
with	NULL
anti-phosphotyrosine	NULL
antibody	NULL
(	NULL
Fig	NULL
.	NULL

4	NULL
,	NULL
A	NULL
and	NULL
B	NULL
)	NULL
.	NULL

In	NULL
addition	NULL
,	NULL
we	NULL
also	NULL
performed	NULL
these	NULL
experiments	NULL
using	NULL
anti-phosphotyrosine	NULL
antibody	NULL
to	NULL
immunoprecipitate	NULL
proteins	NULL
from	NULL
hypoxic	NULL
treated	NULL
cells	NULL
,	NULL
electrophoresed	NULL
the	NULL
immunoprecipitates	NULL
on	NULL
a	NULL
12	NULL
%	NULL
SDS-polyacrylamide	NULL
gel	NULL
,	NULL
and	NULL
then	NULL
probed	NULL
immunoblots	NULL
with	NULL
antibody	NULL
to	NULL
IxBa	NULL
.	NULL

We	NULL
obtained	NULL
the	NULL
same	NULL
results	NULL
with	NULL
either	NULL
of	NULL
the	NULL
above	NULL
described	NULL
protocols	NULL
.	NULL

Although	NULL
these	NULL
data	NULL
indicate	NULL
that	NULL
the	NULL
hypoxia-induced	NULL
dissociation	NULL
and	NULL
degradation	NULL
of	NULL
I	NULL
«	NULL
Ba	NULL
is	NULL
mediated	NULL
by	NULL
its	NULL
tyrosine	NULL
phosphorylation	NULL
status	NULL
,	NULL
it	NULL
is	NULL
possible	NULL
that	NULL
tyrosine	NULL
phosphorylation	NULL
could	NULL
also	NULL
be	NULL
the	NULL
signal	NULL
for	NULL
the	NULL
degradation	NULL
of	NULL
IxBa	NULL
by	NULL
TNF	NULL
or	NULL
PMA	NULL
treatment	NULL
.	NULL

However	NULL
,	NULL
this	NULL
seems	NULL
unlikely	NULL
unless	NULL
IxBa	NULL
is	NULL
degraded	NULL
more	NULL
rapidly	NULL
following	NULL
phosphorylation	NULL
in	NULL
TNF-	NULL
and	NULL
PMA-treated	NULL
cells	NULL
than	NULL
in	NULL
hypoxia-treated	NULL
cells	NULL
.	NULL

In	NULL
these	NULL
Western	NULL
blots	NULL
,	NULL
we	NULL
are	NULL
approaching	NULL
the	NULL
limits	NULL
of	NULL
sensitivity	NULL
in	NULL
detecting	NULL
tyrosine	NULL
phosphorylation	NULL
of	NULL
IxBa	NULL
before	NULL
degradation	NULL
.	NULL

In	NULL
Fig	NULL
.	NULL

14	NULL
,	NULL
25	NULL
ug	NULL
of	NULL
protein	NULL
were	NULL
loaded	NULL
onto	NULL
the	NULL
air	NULL
1	NULL
2	NULL
kBq	NULL
--	NULL
«	NULL
--	NULL
-	NULL
.	NULL

U	NULL
>	NULL
IxBo	NULL
-	NULL
»	NULL
pour	NULL
xone	NULL
stu	NULL
sues	NULL
+	NULL
StAULO	NULL
C	NULL
-	NULL
IrcBa-	NULL
»	NULL
am	NULL
)	NULL
}	NULL
win	NULL
~~	NULL
sam	NULL
+	NULL
herb	NULL
.	NULL

A	NULL
NFB~+-	NULL
@	NULL
é+	NULL
--	NULL
=	NULL
Fig	NULL
.	NULL

3	NULL
.	NULL

Effect	NULL
of	NULL
protein	NULL
kinase	NULL
inhibitors	NULL
on	NULL
IxBa	NULL
degradation	NULL
and	NULL
NF-	NULL
«	NULL
B	NULL
binding	NULL
.	NULL

A	NULL
,	NULL
kinetics	NULL
of	NULL
IxBa	NULL
degradation	NULL
as	NULL
a	NULL
function	NULL
of	NULL
time	NULL
under	NULL
hypoxia	NULL
(	NULL
Ayp	NULL
)	NULL
.	NULL

B	NULL
and	NULL
C	NULL
,	NULL
effect	NULL
of	NULL
protein	NULL
kinase	NULL
inhibitors	NULL
staurosporine	NULL
(	NULL
stauro	NULL
)	NULL
(	NULL
B	NULL
)	NULL
and	NULL
herbimycin	NULL
A	NULL
(	NULL
herb	NULL
.	NULL

A	NULL
)	NULL
(	NULL
C	NULL
)	NULL
on	NULL
IxBa	NULL
degradation	NULL
.	NULL

D	NULL
,	NULL
effect	NULL
of	NULL
staurosporine	NULL
and	NULL
genistein	NULL
on	NULL
hypoxia-induced	NULL
NF-kB	NULL
gel	NULL
which	NULL
allows	NULL
visualization	NULL
of	NULL
IxBa	NULL
in	NULL
air	NULL
and	NULL
shows	NULL
a	NULL
gradual	NULL
disappearance	NULL
of	NULL
the	NULL
protein	NULL
during	NULL
hypoxia	NULL
.	NULL

In	NULL
Fig	NULL
.	NULL

4C	NULL
,	NULL
by	NULL
contrast	NULL
,	NULL
we	NULL
loaded	NULL
150	NULL
ug	NULL
of	NULL
immunoprecipitated	NULL
proteins	NULL
,	NULL
which	NULL
greatly	NULL
binding	NULL
.	NULL

increases	NULL
sensitivity	NULL
in	NULL
detecting	NULL
the	NULL
tyrosine	NULL
phosphorylation	NULL
of	NULL
IxBa	NULL
.	NULL

We	NULL
were	NULL
not	NULL
able	NULL
to	NULL
detect	NULL
tyrosine	NULL
phosphorylation	NULL
of	NULL
I	NULL
«	NULL
Ba	NULL
in	NULL
PMA-	NULL
or	NULL
TNF-treated	NULL
cells	NULL
;	NULL
only	NULL
in	NULL
hypoxia-treated	NULL
cells	NULL
were	NULL
we	NULL
able	NULL
to	NULL
detect	NULL
a	NULL
difference	NULL
in	NULL
tyrosine	NULL
phosphorylation	NULL
.	NULL

To	NULL
determine	NULL
if	NULL
hypoxia	NULL
and	NULL
TNF	NULL
shared	NULL
part	NULL
of	NULL
the	NULL
same	NULL
signaling	NULL
pathway	NULL
for	NULL
IxBa	NULL
degradation	NULL
,	NULL
we	NULL
compared	NULL
the	NULL
effects	NULL
of	NULL
overex-	NULL
scribed	NULL
in	NULL
the	NULL
experiments	NULL
above	NULL
and	NULL
since	NULL
IxBa	NULL
possesses	NULL
a	NULL
potential	NULL
tyrosine	NULL
phosphorylation	NULL
site	NULL
(	NULL
26	NULL
)	NULL
,	NULL
we	NULL
directly	NULL
investigated	NULL
whether	NULL
the	NULL
signal	NULL
for	NULL
IxBa	NULL
to	NULL
dissociate	NULL
from	NULL
NF-	NULL
«	NULL
B	NULL
is	NULL
mediated	NULL
by	NULL
tyrosine	NULL
phosphorylation	NULL
.	NULL

Using	NULL
IxBa-specific	NULL
antibodies	NULL
,	NULL
we	NULL
immunoprecipi-	NULL
Probed	NULL
IP	NULL
with	NULL
IxBa	NULL
,	NULL
probed	NULL
with	NULL
IxBa	NULL
with	NULL
anti-phosphotyrosine	NULL
Time	NULL
of	NULL
PMA	NULL
Time	NULL
of	NULL
PMA	NULL
Treatment	NULL
(	NULL
min	NULL
)	NULL
Treatment	NULL
(	NULL
min	NULL
)	NULL
0	NULL
5	NULL
15	NULL
30	NULL
60	NULL
0	NULL
5	NULL
15	NULL
30	NULL
60	NULL
Fig	NULL
.	NULL

4	NULL
.	NULL

Detection	NULL
of	NULL
tyrosine	NULL
phosphorylation	NULL
of	NULL
Time	NULL
of	NULL
TNF	NULL
Time	NULL
of	NULL
TNF	NULL
IkBa	NULL
usi	NULL
i-phosph	NULL
ine-specifi	NULL
ibod-is	NULL
.	NULL

(	NULL
Left	NULL
panels	NULL
of	NULL
A	NULL
,	NULL
B	NULL
,	NULL
C	NULL
)	NULL
,	NULL
kinctics	NULL
of	NULL
InBa	NULL
Treatment	NULL
(	NULL
min	NULL
)	NULL
Treatment	NULL
(	NULL
min	NULL
)	NULL
degradation	NULL
after	NULL
PMA	NULL
,	NULL
TNFa	NULL
,	NULL
or	NULL
hypoxia	NULL
treatment	NULL
.	NULL

Right	NULL
panels	NULL
of	NULL
A	NULL
,	NULL
B	NULL
,	NULL
Ckainetics	NULL
of	NULL
tyrosine	NULL
0	NULL
>	NULL
5	NULL
15	NULL
30	NULL
.	NULL

60	NULL
F	NULL
0	NULL
5	NULL
1	NULL
sis	NULL
Ly	NULL
y	NULL
phosphorylation	NULL
after	NULL
the	NULL
same	NULL
treatments	NULL
.	NULL

D	NULL
,	NULL
B	NULL
“	NULL
(	NULL
Ba	NULL
wig	NULL
‘	NULL
mm	NULL
£	NULL
~	NULL
;	NULL
analysis	NULL
of	NULL
IxBa	NULL
degradation	NULL
after	NULL
transfection	NULL
of	NULL
cells	NULL
with	NULL
pRSVneo	NULL
or	NULL
Raf301	NULL
and	NULL
treatment	NULL
with	NULL
Time	NULL
under	NULL
Time	NULL
under	NULL
b	NULL
ia	NULL
or	NULL
TNFa	NULL
.	NULL

herb	NULL
.	NULL

A	NULL
,	NULL
herbimycin	NULL
A	NULL
;	NULL
IP	NULL
,	NULL
im-	NULL
x	NULL
hyposia	NULL
or	NULL
®	NULL
herb	NULL
.	NULL

A	NULL
,	NULL
herbimycin	NULL
A	NULL
;	NULL
IP	NULL
,	NULL
im	NULL
Hypoxia	NULL
(	NULL
min	NULL
)	NULL
Hypoxia	NULL
(	NULL
min	NULL
)	NULL
|	NULL
.	NULL

{	NULL
sl	NULL
.	NULL

air	NULL
60	NULL
120	NULL
180	NULL
air	NULL
-	NULL
60	NULL
120	NULL
180	NULL
«	NULL
C	NULL
__	NULL
-	NULL
»	NULL
qpe-am	NULL
.	NULL

-i	NULL
mm	NULL
:	NULL
neo	NULL
raf	NULL
301	NULL
D	NULL
IkBc-	NULL
@	NULL
-	NULL
so	NULL
re	NULL
oe	NULL
B	NULL
-*	NULL
TNF	NULL
-	NULL
-	NULL
+	NULL
*	NULL
=	NULL
+	NULL
hypoxia	NULL
-	NULL
+	NULL
=	NULL
=	NULL
+	NULL
=	NULL
1428	NULL
Downloaded	NULL
from	NULL
cancerres.aacrjournals.org	NULL
on	NULL
May	NULL
10	NULL
,	NULL
2019	NULL
.	NULL

©	NULL
1994	NULL
American	NULL
Association	NULL
for	NULL
Cancer	NULL
Research	NULL
.	NULL

NF-xB	NULL
ACTIVATION	NULL
BY	NULL
HYPOXIA	NULL
pressing	NULL
a	NULL
dominant	NULL
negative	NULL
allele	NULL
of	NULL
Raf-1	NULL
(	NULL
Raf3O01	NULL
)	NULL
on	NULL
the	NULL
degradation	NULL
of	NULL
IxBa	NULL
by	NULL
hypoxia	NULL
or	NULL
TNF	NULL
.	NULL

Raf301	NULL
is	NULL
an	NULL
inactive	NULL
Raf-1	NULL
kinase	NULL
that	NULL
has	NULL
the	NULL
lysine	NULL
of	NULL
its	NULL
ATP-binding	NULL
site	NULL
converted	NULL
to	NULL
tryptophan	NULL
,	NULL
eliminating	NULL
its	NULL
kinase	NULL
activity	NULL
.	NULL

Overexpression	NULL
of	NULL
Raf301	NULL
,	NULL
therefore	NULL
,	NULL
acts	NULL
as	NULL
a	NULL
dominant	NULL
negative	NULL
of	NULL
Raf-1	NULL
by	NULL
specifically	NULL
competing	NULL
for	NULL
the	NULL
same	NULL
substrates	NULL
as	NULL
endogenous	NULL
Raf-1	NULL
(	NULL
42	NULL
)	NULL
.	NULL

The	NULL
degradation	NULL
of	NULL
IxBa	NULL
by	NULL
hypoxia	NULL
was	NULL
almost	NULL
completely	NULL
inhibited	NULL
by	NULL
Raf301	NULL
in	NULL
vivo	NULL
but	NULL
had	NULL
less	NULL
of	NULL
an	NULL
effect	NULL
on	NULL
I	NULL
«	NULL
Ba	NULL
degradation	NULL
by	NULL
TNF	NULL
(	NULL
Fig	NULL
.	NULL

4D	NULL
)	NULL
.	NULL

This	NULL
is	NULL
consistent	NULL
with	NULL
previous	NULL
studies	NULL
which	NULL
have	NULL
shown	NULL
that	NULL
Raf301	NULL
is	NULL
a	NULL
poor	NULL
inhibitor	NULL
of	NULL
transactivation	NULL
of	NULL
a	NULL
plasmid	NULL
containing	NULL
multiple	NULL
«	NULL
B-binding	NULL
sites	NULL
following	NULL
treatment	NULL
with	NULL
TNF	NULL
(	NULL
43	NULL
)	NULL
.	NULL

Control	NULL
trans-fections	NULL
of	NULL
cells	NULL
with	NULL
pRSVneo	NULL
alone	NULL
and	NULL
subsequent	NULL
exposure	NULL
to	NULL
hypoxia	NULL
or	NULL
TNF	NULL
did	NULL
not	NULL
block	NULL
IxBa	NULL
degradation	NULL
by	NULL
either	NULL
of	NULL
these	NULL
stresses	NULL
(	NULL
Fig	NULL
.	NULL

4B	NULL
)	NULL
.	NULL

It	NULL
is	NULL
unlikely	NULL
that	NULL
Raf-1	NULL
kinase	NULL
itself	NULL
is	NULL
directly	NULL
phosphorylating	NULL
IxBa	NULL
as	NULL
it	NULL
is	NULL
a	NULL
serine/threonine	NULL
kinase	NULL
.	NULL

Instead	NULL
Raf-1	NULL
is	NULL
most	NULL
likely	NULL
part	NULL
of	NULL
a	NULL
shared	NULL
pathway	NULL
involved	NULL
in	NULL
signaling	NULL
IxBa	NULL
degradation	NULL
in	NULL
vivo	NULL
by	NULL
diverse	NULL
stresses	NULL
(	NULL
38	NULL
,	NULL
43	NULL
)	NULL
.	NULL

However	NULL
,	NULL
the	NULL
path	NULL
ways	NULL
of	NULL
NF-	NULL
«	NULL
B	NULL
activation	NULL
seem	NULL
to	NULL
diverge	NULL
because	NULL
TNF	NULL
and	NULL
PMA	NULL
|	NULL
'*	NULL
do	NULL
not	NULL
result	NULL
in	NULL
detectable	NULL
tyrosine	NULL
phosphorylation	NULL
of	NULL
IxBa	NULL
.	NULL

What	NULL
is	NULL
the	NULL
physiological	NULL
significance	NULL
of	NULL
NF-	NULL
«	NULL
B	NULL
activation	NULL
by	NULL
-	NULL
11.	NULL
hypoxia	NULL
in	NULL
a	NULL
tumor	NULL
?	NULL

Once	NULL
a	NULL
tumor	NULL
grows	NULL
beyond	NULL
100	NULL
mm	NULL
in	NULL
diameter	NULL
,	NULL
it	NULL
may	NULL
develop	NULL
areas	NULL
of	NULL
hypoxia	NULL
since	NULL
O	NULL
;	NULL
and	NULL
nutrients	NULL
will	NULL
poorly	NULL
|	NULL
12.	NULL
diffuse	NULL
beyond	NULL
this	NULL
distance	NULL
.	NULL

Because	NULL
diffusion	NULL
of	NULL
O	NULL
;	NULL
is	NULL
a	NULL
limiting	NULL
factor	NULL
in	NULL
the	NULL
growth	NULL
of	NULL
a	NULL
tumor	NULL
,	NULL
the	NULL
tumor	NULL
secretes	NULL
chemotactic	NULL
signals	NULL
|	NULL
;	NULL
;	NULL
in	NULL
the	NULL
form	NULL
of	NULL
growth	NULL
factors	NULL
and	NULL
cytokines	NULL
to	NULL
induce	NULL
neovascular-ization	NULL
(	NULL
44	NULL
)	NULL
.	NULL

Many	NULL
of	NULL
the	NULL
cytokines	NULL
involved	NULL
in	NULL
this	NULL
process	NULL
possess	NULL
-	NULL
'*	NULL
NF-	NULL
«	NULL
B-binding	NULL
elements	NULL
(	NULL
45-47	NULL
)	NULL
.	NULL

The	NULL
induction	NULL
of	NULL
NF-	NULL
«	NULL
B	NULL
by	NULL
hypoxia	NULL
fits	NULL
its	NULL
role	NULL
as	NULL
a	NULL
genetic	NULL
regulatory	NULL
mechanism	NULL
activated	NULL
in	NULL
-	NULL
15.	NULL
response	NULL
to	NULL
the	NULL
stress	NULL
of	NULL
low	NULL
oxygen	NULL
conditions	NULL
.	NULL

In	NULL
the	NULL
case	NULL
of	NULL
a	NULL
rapidly	NULL
dividing	NULL
tumor	NULL
,	NULL
the	NULL
activation	NULL
of	NULL
NF-	NULL
«	NULL
B	NULL
would	NULL
be	NULL
essential	NULL
for	NULL
_	NULL
16	NULL
,	NULL
the	NULL
recruitment	NULL
of	NULL
new	NULL
blood	NULL
vessels	NULL
so	NULL
that	NULL
the	NULL
growth	NULL
of	NULL
the	NULL
tumor	NULL
is	NULL
not	NULL
impeded	NULL
by	NULL
a	NULL
lack	NULL
of	NULL
O	NULL
;	NULL
,	NULL
and	NULL
other	NULL
essential	NULL
nutrients	NULL
.	NULL

In	NULL
addition	NULL
,	NULL
there	NULL
is	NULL
evidence	NULL
that	NULL
the	NULL
p65	NULL
subunit	NULL
plays	NULL
a	NULL
role	NULL
in	NULL
medi-	NULL
-	NULL
17.	NULL
ating	NULL
cellular	NULL
adhesion	NULL
and	NULL
tumorigenesis	NULL
(	NULL
48	NULL
)	NULL
.	NULL

In	NULL
that	NULL
regions	NULL
of	NULL
hypoxia	NULL
are	NULL
a	NULL
common	NULL
feature	NULL
of	NULL
many	NULL
solid	NULL
tumors	NULL
,	NULL
hypoxia	NULL
may	NULL
|	NULL
1s	NULL
,	NULL
also	NULL
contribute	NULL
to	NULL
tumorigenesis	NULL
through	NULL
its	NULL
activation	NULL
of	NULL
NF-KB	NULL
.	NULL

Solid	NULL
tumors	NULL
undergo	NULL
sporadic	NULL
opening	NULL
and	NULL
closing	NULL
of	NULL
their	NULL
vascula-	NULL
-	NULL
,	NULL
,	NULL
ture	NULL
resulting	NULL
in	NULL
areas	NULL
of	NULL
acute	NULL
hypoxia	NULL
which	NULL
experience	NULL
a	NULL
burst	NULL
of	NULL
free	NULL
radicals	NULL
upon	NULL
reoxygenation	NULL
(	NULL
49	NULL
)	NULL
.	NULL

Since	NULL
oxidative	NULL
stress	NULL
and	NULL
hypoxia	NULL
are	NULL
potent	NULL
activators	NULL
of	NULL
NF-	NULL
«	NULL
B	NULL
,	NULL
both	NULL
factors	NULL
could	NULL
act	NULL
to	NULL
20	NULL
increase	NULL
the	NULL
activation	NULL
of	NULL
NF-	NULL
«	NULL
B	NULL
in	NULL
solid	NULL
tumors	NULL
.	NULL

21	NULL
.	NULL

The	NULL
work	NULL
presented	NULL
in	NULL
this	NULL
paper	NULL
shows	NULL
that	NULL
tyrosine	NULL
phosphorylation	NULL
is	NULL
a	NULL
required	NULL
event	NULL
for	NULL
NF-	NULL
«	NULL
B	NULL
activation	NULL
by	NULL
hypoxia	NULL
.	NULL

Further-	NULL
-	NULL
;	NULL
;	NULL
more	NULL
,	NULL
hypoxia	NULL
appears	NULL
to	NULL
modulate	NULL
the	NULL
cascade	NULL
of	NULL
events	NULL
leading	NULL
to	NULL
NF-	NULL
«	NULL
B	NULL
activation	NULL
in	NULL
a	NULL
different	NULL
manner	NULL
than	NULL
other	NULL
stresses	NULL
such	NULL
as	NULL
23	NULL
treatment	NULL
with	NULL
PMA	NULL
or	NULL
TNF	NULL
.	NULL

These	NULL
results	NULL
do	NULL
not	NULL
preclude	NULL
the	NULL
possibility	NULL
that	NULL
other	NULL
stresses	NULL
or	NULL
cytokines	NULL
mediate	NULL
IxBa	NULL
dissociation	NULL
-	NULL
24	NULL
directly	NULL
through	NULL
a	NULL
serine/threonine	NULL
phosphorylation	NULL
event	NULL
.	NULL

In	NULL
fact	NULL
,	NULL
the	NULL
phosphorylation	NULL
of	NULL
IxBa	NULL
on	NULL
serine	NULL
or	NULL
tyrosine	NULL
residues	NULL
may	NULL
be	NULL
the	NULL
-	NULL
25	NULL
mechanism	NULL
that	NULL
differentially	NULL
regulates	NULL
its	NULL
degradation	NULL
after	NULL
different	NULL
stresses	NULL
.	NULL

Identification	NULL
of	NULL
the	NULL
tyrosine	NULL
kinase	NULL
involved	NULL
in	NULL
phosphory-	NULL
_	NULL
,	NULL
,	NULL
lating	NULL
IxBa	NULL
by	NULL
hypoxia	NULL
would	NULL
present	NULL
a	NULL
potential	NULL
therapeutic	NULL
target	NULL
to	NULL
inhibit	NULL
NF-	NULL
«	NULL
B-mediated	NULL
gene	NULL
expression	NULL
in	NULL
solid	NULL
tumors	NULL
.	NULL

27	NULL
.	NULL

Acknowledgments	NULL
We	NULL
thank	NULL
Dr.	NULL
Gary	NULL
Nolan	NULL
for	NULL
many	NULL
belpful	NULL
discussions	NULL
.	NULL

We	NULL
also	NULL
thank	NULL
Virginia	NULL
Chambers	NULL
for	NULL
help	NULL
in	NULL
the	NULL
preparation	NULL
of	NULL
the	NULL
manuscript	NULL
.	NULL

28	NULL
.	NULL

References	NULL
29	NULL
.	NULL

1	NULL
.	NULL

Moulder	NULL
,	NULL
J.	NULL
E.	NULL
,	NULL
and	NULL
Rockwell	NULL
,	NULL
S.	NULL
Tumor	NULL
hypoxia	NULL
:	NULL
its	NULL
impact	NULL
on	NULL
cancer	NULL
therapy	NULL
.	NULL

Cancer	NULL
_	NULL
30	NULL
.	NULL

Metastasis	NULL
Rev	NULL
.	NULL

,	NULL
5	NULL
:	NULL
313-341	NULL
,	NULL
1987	NULL
.	NULL

2	NULL
.	NULL

Gatenby	NULL
,	NULL
R.	NULL
A.	NULL
,	NULL
Kessler	NULL
,	NULL
H.	NULL
B.	NULL
,	NULL
Rosenblum	NULL
,	NULL
J.	NULL
S.	NULL
,	NULL
Coia	NULL
,	NULL
L.	NULL
R.	NULL
,	NULL
Moldofsky	NULL
,	NULL
P.	NULL
J.	NULL
,	NULL
Hartz	NULL
,	NULL
W.	NULL
H.	NULL
,	NULL
and	NULL
Broder	NULL
,	NULL
G.	NULL
J	NULL
.	NULL

Oxygen	NULL
distribution	NULL
in	NULL
squamous	NULL
cell	NULL
carcinoma	NULL
metastases	NULL
|	NULL
31	NULL
.	NULL

1429	NULL
and	NULL
its	NULL
relationship	NULL
to	NULL
outcome	NULL
of	NULL
radiation	NULL
therapy	NULL
.	NULL

Int	NULL
.	NULL

J.	NULL
Radiat	NULL
.	NULL

Oncol	NULL
.	NULL

Biol	NULL
.	NULL

Phys	NULL
.	NULL

,	NULL
14	NULL
:	NULL
831-838	NULL
,	NULL
1988.	NULL
.	NULL

Bush	NULL
,	NULL
R.	NULL
S.	NULL
,	NULL
Jenkin	NULL
,	NULL
R.	NULL
D.	NULL
T.	NULL
,	NULL
Allt	NULL
,	NULL
W.	NULL
E.	NULL
C.	NULL
,	NULL
Beale	NULL
,	NULL
F.	NULL
A.	NULL
,	NULL
Bean	NULL
,	NULL
H.	NULL
,	NULL
Denbo	NULL
,	NULL
A.	NULL
J.	NULL
,	NULL
and	NULL
Pringle	NULL
,	NULL
J.	NULL
F.	NULL
Definite	NULL
evidence	NULL
for	NULL
hypoxic	NULL
cells	NULL
influencing	NULL
cure	NULL
in	NULL
cancer	NULL
therapy	NULL
.	NULL

Br	NULL
.	NULL

J	NULL
.	NULL

Cancer	NULL
,	NULL
37	NULL
(	NULL
Suppl	NULL
.	NULL

3	NULL
)	NULL
:	NULL
302-306	NULL
,	NULL
1978.	NULL
.	NULL

Heacock	NULL
,	NULL
C.	NULL
S.	NULL
,	NULL
and	NULL
Sutherland	NULL
,	NULL
R.	NULL
M.	NULL
Enhanced	NULL
synthesis	NULL
of	NULL
stress	NULL
proteins	NULL
caused	NULL
by	NULL
hypoxia	NULL
and	NULL
relation	NULL
to	NULL
altered	NULL
cell	NULL
growth	NULL
and	NULL
metabolism	NULL
.	NULL

Br	NULL
.	NULL

J	NULL
.	NULL

Cancer	NULL
,	NULL
62	NULL
:	NULL
217-225	NULL
,	NULL
1990.	NULL
.	NULL

Koong	NULL
,	NULL
A.	NULL
C.	NULL
,	NULL
Auger	NULL
,	NULL
E.	NULL
A.	NULL
,	NULL
Chen	NULL
,	NULL
E.	NULL
Y.	NULL
,	NULL
and	NULL
Giaccia	NULL
,	NULL
A.	NULL
J	NULL
.	NULL

The	NULL
regulation	NULL
of	NULL
GRP78	NULL
protein	NULL
and	NULL
messenger	NULL
RNA	NULL
levels	NULL
by	NULL
hypoxia	NULL
is	NULL
modulated	NULL
by	NULL
protein	NULL
kinase	NULL
C	NULL
activators	NULL
and	NULL
inhibitors	NULL
.	NULL

Radiat	NULL
.	NULL

Res	NULL
.	NULL

,	NULL
in	NULL
press	NULL
,	NULL
1994.	NULL
.	NULL

Graeber	NULL
,	NULL
S.	NULL
E.	NULL
,	NULL
and	NULL
Krantz	NULL
,	NULL
S.	NULL
B.	NULL
Erythropoietin	NULL
:	NULL
biology	NULL
and	NULL
clinical	NULL
use	NULL
.	NULL

Hematol	NULL
.	NULL

Ocol	NULL
.	NULL

Clin	NULL
.	NULL

North	NULL
Am	NULL
.	NULL

,	NULL
3	NULL
:	NULL
369	NULL
,	NULL
1989.	NULL
.	NULL

Semenza	NULL
,	NULL
G.	NULL
L.	NULL
,	NULL
and	NULL
Wang	NULL
,	NULL
G.	NULL
L.	NULL
A	NULL
nuclear	NULL
factor	NULL
induced	NULL
by	NULL
hypoxia	NULL
via	NULL
de	NULL
novo	NULL
protein	NULL
synthesis	NULL
binds	NULL
to	NULL
the	NULL
human	NULL
erythropoietin	NULL
gene	NULL
enhancer	NULL
at	NULL
a	NULL
site	NULL
required	NULL
for	NULL
transcriptional	NULL
activation	NULL
.	NULL

Mol	NULL
.	NULL

Cell	NULL
.	NULL

Biol	NULL
.	NULL

,	NULL
12	NULL
:	NULL
5447-5454	NULL
,	NULL
1992.	NULL
.	NULL

Giaccia	NULL
,	NULL
A.	NULL
J.	NULL
,	NULL
Auger	NULL
,	NULL
E.	NULL
A.	NULL
,	NULL
Koong	NULL
,	NULL
A.	NULL
,	NULL
Terrace	NULL
,	NULL
D.	NULL
,	NULL
Minchinton	NULL
,	NULL
A.	NULL
,	NULL
Hahn	NULL
,	NULL
G.	NULL
M.	NULL
,	NULL
and	NULL
Brown	NULL
,	NULL
J.	NULL
M.	NULL
Activation	NULL
of	NULL
the	NULL
heat	NULL
shock	NULL
transcription	NULL
factor	NULL
by	NULL
hypoxia	NULL
in	NULL
normal	NULL
and	NULL
tumor	NULL
cell	NULL
lines	NULL
in	NULL
vivo	NULL
and	NULL
in	NULL
vitro	NULL
.	NULL

Int	NULL
.	NULL

J.	NULL
Radiat	NULL
.	NULL

Oncol	NULL
.	NULL

Biol	NULL
.	NULL

Phys	NULL
.	NULL

,	NULL
23	NULL
:	NULL
891-897	NULL
,	NULL
1992.	NULL
.	NULL

Molitor	NULL
,	NULL
J	NULL
.	NULL

A.	NULL
,	NULL
Walker	NULL
,	NULL
W.	NULL
H.	NULL
,	NULL
Doerre	NULL
,	NULL
S.	NULL
,	NULL
Ballard	NULL
,	NULL
D.	NULL
W.	NULL
,	NULL
and	NULL
Greene	NULL
,	NULL
W.	NULL
C.	NULL
NF-	NULL
«	NULL
B	NULL
;	NULL
a	NULL
family	NULL
of	NULL
inducible	NULL
and	NULL
differentially	NULL
expressed	NULL
enhancer-binding	NULL
proteins	NULL
in	NULL
human	NULL
T	NULL
cells	NULL
.	NULL

Proc	NULL
.	NULL

Natl	NULL
.	NULL

Acad	NULL
.	NULL

Sci	NULL
.	NULL

USA	NULL
,	NULL
87	NULL
:	NULL
10028-10032	NULL
,	NULL
1990	NULL
.	NULL

Perkins	NULL
,	NULL
N.	NULL
D.	NULL
,	NULL
Schmid	NULL
,	NULL
R.	NULL
M.	NULL
,	NULL
Duckett	NULL
,	NULL
C.	NULL
S.	NULL
,	NULL
Leung	NULL
,	NULL
K.	NULL
,	NULL
Rice	NULL
,	NULL
N.	NULL
R.	NULL
,	NULL
and	NULL
Nabel	NULL
,	NULL
G.	NULL
J	NULL
.	NULL

Distinct	NULL
combinations	NULL
of	NULL
NF-xB	NULL
subunits	NULL
determine	NULL
the	NULL
specificity	NULL
of	NULL
transcriptional	NULL
activation	NULL
.	NULL

Proc	NULL
.	NULL

Natl	NULL
.	NULL

Acad	NULL
.	NULL

Sci	NULL
.	NULL

USA	NULL
,	NULL
89	NULL
:	NULL
1529-1533	NULL
,	NULL
1992	NULL
.	NULL

Radler-Poh	NULL
!	NULL

,	NULL
A.	NULL
,	NULL
Pfeuffer	NULL
,	NULL
I.	NULL
,	NULL
Karin	NULL
,	NULL
M.	NULL
,	NULL
and	NULL
Sterfling	NULL
,	NULL
E.	NULL
A	NULL
novel	NULL
T-cell	NULL
rrans-activator	NULL
that	NULL
recognizes	NULL
a	NULL
phorbol	NULL
ester-inducible	NULL
element	NULL
of	NULL
the	NULL
interleukin-2	NULL
promotor	NULL
.	NULL

New	NULL
Biol	NULL
.	NULL

,	NULL
2	NULL
:	NULL
566-573	NULL
,	NULL
1990	NULL
.	NULL

Bacuerle	NULL
,	NULL
P.	NULL
A.	NULL
,	NULL
and	NULL
Baltimore	NULL
,	NULL
D.	NULL
The	NULL
physiology	NULL
of	NULL
the	NULL
NF-	NULL
«	NULL
B	NULL
transcription	NULL
factor	NULL
.	NULL

In	NULL
:	NULL
P.	NULL
Cohen	NULL
and	NULL
J.	NULL
G.	NULL
Foulkes	NULL
(	NULL
eds	NULL
.	NULL
)	NULL

,	NULL
Molecular	NULL
Aspects	NULL
of	NULL
Cellular	NULL
Regulation	NULL
pp	NULL
.	NULL

409-432	NULL
.	NULL

Amsterdam	NULL
:	NULL
Elseviier/North-Holland	NULL
Biomedical	NULL
Press	NULL
,	NULL
1991	NULL
.	NULL

Leonardo	NULL
,	NULL
M.	NULL
J.	NULL
,	NULL
and	NULL
Baltimore	NULL
,	NULL
D.	NULL
NF-	NULL
«	NULL
B	NULL
:	NULL
a	NULL
pleiotrophic	NULL
mediator	NULL
of	NULL
inducible	NULL
and	NULL
tissue	NULL
specific	NULL
gene	NULL
control	NULL
.	NULL

Cell	NULL
,	NULL
58	NULL
:	NULL
227-229	NULL
,	NULL
1989	NULL
.	NULL

Brach	NULL
,	NULL
M.	NULL
A.	NULL
,	NULL
Hass	NULL
,	NULL
R.	NULL
,	NULL
Sherman	NULL
,	NULL
M.	NULL
L.	NULL
,	NULL
Gunji	NULL
,	NULL
H.	NULL
,	NULL
Weichselbaum	NULL
,	NULL
R.	NULL
R.	NULL
,	NULL
and	NULL
Kufe	NULL
,	NULL
D.	NULL
lonizing	NULL
radiation	NULL
induces	NULL
expression	NULL
and	NULL
binding	NULL
activity	NULL
of	NULL
the	NULL
nuclear	NULL
factor	NULL
«	NULL
B	NULL
.	NULL

J.	NULL
Clin	NULL
.	NULL

Invest	NULL
.	NULL

,	NULL
88	NULL
:	NULL
691-695	NULL
,	NULL
1991	NULL
.	NULL

Ghosh	NULL
,	NULL
S.	NULL
,	NULL
Gifford	NULL
,	NULL
A.	NULL
M.	NULL
,	NULL
Riviere	NULL
,	NULL
L.	NULL
R.	NULL
,	NULL
Tempst	NULL
,	NULL
P.	NULL
,	NULL
Nolan	NULL
,	NULL
G.	NULL
P.	NULL
,	NULL
and	NULL
Baltimore	NULL
,	NULL
D.	NULL
Cloning	NULL
of	NULL
the	NULL
p50	NULL
DNA	NULL
binding	NULL
subunit	NULL
of	NULL
NF-kB	NULL
:	NULL
homology	NULL
to	NULL
re	NULL
?	NULL

and	NULL
dorsal	NULL
.	NULL

Cell	NULL
,	NULL
62	NULL
:	NULL
1019-1029	NULL
,	NULL
1990	NULL
.	NULL

Neri	NULL
,	NULL
A.	NULL
,	NULL
Chang	NULL
,	NULL
C-C.	NULL
,	NULL
Lombardi	NULL
,	NULL
L.	NULL
,	NULL
Salina	NULL
,	NULL
M.	NULL
,	NULL
Corradini	NULL
,	NULL
P.	NULL
,	NULL
Maiolto	NULL
,	NULL
A.	NULL
T.	NULL
,	NULL
Changa-nti	NULL
,	NULL
R.	NULL
S.	NULL
K.	NULL
,	NULL
and	NULL
Dalla-Favera	NULL
,	NULL
R.	NULL
B	NULL
cell	NULL
lymphoma-associated	NULL
chromosomal	NULL
translocation	NULL
involves	NULL
candidate	NULL
oncogene	NULL
,	NULL
lyt-10	NULL
,	NULL
homologous	NULL
to	NULL
NFkB	NULL
pSO	NULL
.	NULL

Cell	NULL
,	NULL
67	NULL
:	NULL
1075-1087	NULL
,	NULL
1991	NULL
.	NULL

Nolan	NULL
,	NULL
G.	NULL
P.	NULL
,	NULL
Ghosh	NULL
,	NULL
S.	NULL
,	NULL
Liou	NULL
,	NULL
H-C.	NULL
,	NULL
Tempst	NULL
,	NULL
P.	NULL
,	NULL
and	NULL
Baltimore	NULL
,	NULL
D.	NULL
DNA	NULL
binding	NULL
and	NULL
IxB	NULL
inhibition	NULL
of	NULL
the	NULL
cloned	NULL
p65	NULL
subunit	NULL
of	NULL
NFB	NULL
,	NULL
a	NULL
rel-related	NULL
polypeptide	NULL
.	NULL

Cell	NULL
,	NULL
64	NULL
:	NULL
961-969	NULL
,	NULL
1991	NULL
.	NULL

Ryseck	NULL
,	NULL
R.	NULL
P.	NULL
,	NULL
Bull	NULL
,	NULL
P.	NULL
,	NULL
Takamiya	NULL
,	NULL
M.	NULL
,	NULL
Bours	NULL
,	NULL
V.	NULL
,	NULL
Siebenlist	NULL
,	NULL
U.	NULL
,	NULL
Dobrzanski	NULL
,	NULL
P.	NULL
,	NULL
and	NULL
Bravo	NULL
,	NULL
R.	NULL
RelB	NULL
,	NULL
a	NULL
new	NULL
Rel	NULL
family	NULL
transcription	NULL
activator	NULL
that	NULL
can	NULL
interact	NULL
with	NULL
p50-NFB	NULL
.	NULL

Mol	NULL
.	NULL

Cell	NULL
.	NULL

Biol	NULL
.	NULL

,	NULL
12	NULL
:	NULL
674-684	NULL
,	NULL
1992	NULL
.	NULL

Stephens	NULL
,	NULL
R.	NULL
M.	NULL
,	NULL
Rice	NULL
,	NULL
N.	NULL
R.	NULL
,	NULL
Hiebsch	NULL
,	NULL
R.	NULL
R.	NULL
,	NULL
Bose	NULL
,	NULL
H.	NULL
R.	NULL
,	NULL
and	NULL
Gilden	NULL
,	NULL
R.	NULL
V.	NULL
Nucleotide	NULL
sequence	NULL
of	NULL
v-rel	NULL
:	NULL
the	NULL
oncogene	NULL
of	NULL
reticuloendotheliosis	NULL
virus	NULL
.	NULL

Proc	NULL
.	NULL

Natl	NULL
.	NULL

Acad	NULL
.	NULL

Sci	NULL
.	NULL

USA	NULL
,	NULL
80	NULL
:	NULL
6229-6233	NULL
,	NULL
1983.	NULL
.	NULL

Steward	NULL
,	NULL
R.	NULL
Dorsal	NULL
,	NULL
an	NULL
embryonic	NULL
polarity	NULL
gene	NULL
in	NULL
Drosophila	NULL
,	NULL
is	NULL
homologous	NULL
to	NULL
the	NULL
vertebrate	NULL
proto-onogene	NULL
,	NULL
c-rel	NULL
.	NULL

Science	NULL
(	NULL
Washington	NULL
DC	NULL
)	NULL
,	NULL
238	NULL
:	NULL
692-694	NULL
,	NULL
1987	NULL
.	NULL

Ballard	NULL
,	NULL
D.	NULL
W.	NULL
,	NULL
Walker	NULL
,	NULL
W.	NULL
H.	NULL
,	NULL
Doerre	NULL
,	NULL
S.	NULL
,	NULL
Sista	NULL
,	NULL
P.	NULL
,	NULL
Molitor	NULL
,	NULL
J	NULL
.	NULL

A.	NULL
,	NULL
Dixon	NULL
,	NULL
E.	NULL
P.	NULL
,	NULL
Peffer	NULL
,	NULL
N.	NULL
J.	NULL
,	NULL
Hannink	NULL
,	NULL
M.	NULL
,	NULL
and	NULL
Greene	NULL
,	NULL
W.	NULL
C.	NULL
The	NULL
v-re/	NULL
oncogene	NULL
encodes	NULL
a	NULL
«	NULL
B	NULL
enhancer	NULL
binding	NULL
protein	NULL
that	NULL
inhibits	NULL
NF-KB	NULL
function	NULL
.	NULL

Cell	NULL
,	NULL
63	NULL
:	NULL
803-814	NULL
,	NULL
1990.	NULL
.	NULL

Mercurio	NULL
,	NULL
F.	NULL
,	NULL
Didonato	NULL
,	NULL
J	NULL
.	NULL

A.	NULL
,	NULL
Rosette	NULL
,	NULL
C.	NULL
,	NULL
and	NULL
Karin	NULL
,	NULL
M.	NULL
p105	NULL
and	NULL
p98	NULL
precursor	NULL
proteins	NULL
play	NULL
an	NULL
active	NULL
role	NULL
in	NULL
NF-kB	NULL
mediated	NULL
signal	NULL
transduction	NULL
.	NULL

Genes	NULL
&	NULL
Dev	NULL
.	NULL

,	NULL
7	NULL
:	NULL
705-718	NULL
,	NULL
1993.	NULL
.	NULL

Rice	NULL
,	NULL
N.	NULL
R.	NULL
,	NULL
MacKichan	NULL
,	NULL
M.	NULL
L.	NULL
,	NULL
and	NULL
Israel	NULL
,	NULL
A	NULL
.	NULL

The	NULL
precursor	NULL
of	NULL
NF-B	NULL
pSO	NULL
has	NULL
IxB	NULL
like	NULL
functions	NULL
.	NULL

Cell	NULL
,	NULL
77	NULL
:	NULL
243-253	NULL
,	NULL
1992.	NULL
.	NULL

Davis	NULL
,	NULL
N.	NULL
S.	NULL
,	NULL
Ghosh	NULL
,	NULL
S.	NULL
,	NULL
Simmons	NULL
,	NULL
D.	NULL
L.	NULL
,	NULL
Tempst	NULL
,	NULL
P.	NULL
,	NULL
Liou	NULL
,	NULL
H-C.	NULL
,	NULL
Baltimore	NULL
,	NULL
D.	NULL
,	NULL
and	NULL
Bose	NULL
,	NULL
H.	NULL
R.	NULL
Rel-associated	NULL
pp40	NULL
:	NULL
an	NULL
inhibitor	NULL
of	NULL
the	NULL
Rel	NULL
family	NULL
of	NULL
transcription	NULL
factors	NULL
.	NULL

Science	NULL
(	NULL
Washington	NULL
DC	NULL
)	NULL
,	NULL
253	NULL
:	NULL
1268-1271	NULL
,	NULL
1991.	NULL
.	NULL

Franzoso	NULL
,	NULL
G.	NULL
,	NULL
Bours	NULL
,	NULL
V.	NULL
,	NULL
Park	NULL
,	NULL
S.	NULL
,	NULL
Tomita-	NULL
Yamaguchi	NULL
,	NULL
M.	NULL
,	NULL
Kelly	NULL
,	NULL
K.	NULL
,	NULL
and	NULL
Sicbenlist	NULL
,	NULL
U	NULL
.	NULL

The	NULL
candidate	NULL
oncoprotein	NULL
Bel-3	NULL
is	NULL
an	NULL
antagonist	NULL
of	NULL
pS0/NF-	NULL
«	NULL
kB	NULL
mediated	NULL
inhibition	NULL
.	NULL

Nature	NULL
(	NULL
Lond	NULL
.	NULL
)	NULL

,	NULL
359	NULL
:	NULL
339-342	NULL
,	NULL
1992.	NULL
.	NULL

Haskill	NULL
,	NULL
S.	NULL
,	NULL
Beg	NULL
,	NULL
A	NULL
.	NULL

A.	NULL
,	NULL
Thompkins	NULL
,	NULL
S.	NULL
M.	NULL
,	NULL
Morris	NULL
,	NULL
J.	NULL
S.	NULL
,	NULL
Yurochko	NULL
,	NULL
A.	NULL
D.	NULL
,	NULL
Sampson	NULL
Johannes	NULL
,	NULL
A.	NULL
,	NULL
Mondal	NULL
,	NULL
K.	NULL
,	NULL
Ralph	NULL
,	NULL
P.	NULL
,	NULL
and	NULL
Baldwin	NULL
,	NULL
A.	NULL
S.	NULL
Characterization	NULL
of	NULL
an	NULL
immediate-early	NULL
gene	NULL
induced	NULL
in	NULL
aderent	NULL
monocytes	NULL
that	NULL
encodes	NULL
IxB-like	NULL
activity	NULL
.	NULL

Cell	NULL
,	NULL
65	NULL
:	NULL
1281-1289	NULL
,	NULL
1991	NULL
.	NULL

Hatada	NULL
,	NULL
E.	NULL
N.	NULL
,	NULL
Nieters	NULL
,	NULL
A.	NULL
,	NULL
Wulczyn	NULL
,	NULL
F.	NULL
G.	NULL
,	NULL
Naumann	NULL
,	NULL
M.	NULL
,	NULL
Meyer	NULL
,	NULL
R.	NULL
,	NULL
Nucifora	NULL
,	NULL
G.	NULL
,	NULL
McKeithan	NULL
,	NULL
T.	NULL
W.	NULL
,	NULL
and	NULL
Scheidereit	NULL
,	NULL
C.	NULL
The	NULL
ankyrin	NULL
repeat	NULL
domains	NULL
of	NULL
the	NULL
NF-xB	NULL
precursor	NULL
p105	NULL
and	NULL
the	NULL
proto-oncogene	NULL
be/-3	NULL
act	NULL
as	NULL
specific	NULL
inhibitors	NULL
of	NULL
NF-	NULL
«	NULL
B	NULL
DNA	NULL
binding	NULL
.	NULL

Proc	NULL
.	NULL

Natl	NULL
.	NULL

Acad	NULL
.	NULL

Sci	NULL
.	NULL

USA	NULL
,	NULL
89	NULL
:	NULL
2489-2493	NULL
,	NULL
1992.	NULL
.	NULL

Inoue	NULL
,	NULL
J-L	NULL
,	NULL
Kerr	NULL
,	NULL
L.	NULL
D.	NULL
,	NULL
Kakizuka	NULL
,	NULL
A.	NULL
,	NULL
and	NULL
Verma	NULL
,	NULL
I.	NULL
M.	NULL
IkBg	NULL
,	NULL
a	NULL
70	NULL
kd	NULL
protein	NULL
identical	NULL
to	NULL
the	NULL
C-terminal	NULL
half	NULL
of	NULL
p110	NULL
NF-	NULL
«	NULL
B	NULL
:	NULL
a	NULL
new	NULL
member	NULL
of	NULL
the	NULL
IxB	NULL
family	NULL
.	NULL

Cell	NULL
,	NULL
68	NULL
:	NULL
1109-1120	NULL
,	NULL
1992	NULL
.	NULL

Ghosh	NULL
,	NULL
S.	NULL
,	NULL
and	NULL
Baltimore	NULL
,	NULL
D.	NULL
Activation	NULL
in	NULL
vitro	NULL
of	NULL
NF-xB	NULL
by	NULL
phosphorylation	NULL
of	NULL
its	NULL
inhibitor	NULL
IB	NULL
.	NULL

Nature	NULL
(	NULL
Lond	NULL
.	NULL
)	NULL

,	NULL
344	NULL
:	NULL
678-682	NULL
,	NULL
1990	NULL
.	NULL

Shirakawa	NULL
,	NULL
F.	NULL
,	NULL
and	NULL
Mizel	NULL
,	NULL
S.	NULL
B	NULL
.	NULL

In	NULL
vitro	NULL
activation	NULL
and	NULL
nuclear	NULL
translocation	NULL
of	NULL
NF-xB	NULL
catalyzed	NULL
by	NULL
the	NULL
cyclic	NULL
AMP-dependent	NULL
protein	NULL
kinase	NULL
and	NULL
protein	NULL
kinase	NULL
C.	NULL
Mol	NULL
.	NULL

Cell	NULL
.	NULL

Biol	NULL
.	NULL

,	NULL
9	NULL
:	NULL
2424-2430	NULL
,	NULL
1989	NULL
.	NULL

Beg	NULL
,	NULL
A	NULL
.	NULL

A.	NULL
,	NULL
Finco	NULL
,	NULL
T.	NULL
S.	NULL
,	NULL
Nantermet	NULL
,	NULL
P.	NULL
V.	NULL
,	NULL
and	NULL
Baldwin	NULL
,	NULL
A.	NULL
S.	NULL
Tumor	NULL
necrosis	NULL
factor	NULL
Downloaded	NULL
from	NULL
cancerres.aacrjournals.org	NULL
on	NULL
May	NULL
10	NULL
,	NULL
2019	NULL
.	NULL

©	NULL
1994	NULL
American	NULL
Association	NULL
for	NULL
Cancer	NULL
Research	NULL
.	NULL

32	NULL
.	NULL

33	NULL
.	NULL

35	NULL
.	NULL

37	NULL
.	NULL

38	NULL
.	NULL

39	NULL
.	NULL

NF-kB	NULL
ACTIVATION	NULL
BY	NULL
HYPOXIA	NULL
and	NULL
interleukin-1	NULL
lead	NULL
to	NULL
phophorylation	NULL
and	NULL
loss	NULL
of	NULL
IxBa	NULL
:	NULL
a	NULL
mechanism	NULL
for	NULL
NF-kB	NULL
activation	NULL
.	NULL

Mol	NULL
.	NULL

Cell	NULL
.	NULL

Biol	NULL
.	NULL

,	NULL
13	NULL
:	NULL
3301-3310	NULL
,	NULL
1993	NULL
.	NULL

Polonis	NULL
,	NULL
V.	NULL
R.	NULL
,	NULL
Anderson	NULL
,	NULL
G.	NULL
R.	NULL
,	NULL
Vahey	NULL
,	NULL
M.	NULL
T.	NULL
,	NULL
Morrow	NULL
,	NULL
P.	NULL
J.	NULL
,	NULL
Stoler	NULL
,	NULL
D.	NULL
,	NULL
and	NULL
Redfield	NULL
,	NULL
R.	NULL
R.	NULL
Anoxia	NULL
induces	NULL
human	NULL
immunodeficiency	NULL
virus	NULL
in	NULL
infected	NULL
T	NULL
cell	NULL
lines	NULL
.	NULL

J.	NULL
Biol	NULL
.	NULL

Chem	NULL
.	NULL

,	NULL
266	NULL
:	NULL
11421-11424	NULL
,	NULL
1991	NULL
.	NULL

Fordis	NULL
,	NULL
C.	NULL
M.	NULL
,	NULL
and	NULL
Howard	NULL
,	NULL
B.	NULL
H.	NULL
Use	NULL
of	NULL
CAT	NULL
reporter	NULL
gene	NULL
for	NULL
optimization	NULL
of	NULL
gene	NULL
transfer	NULL
into	NULL
eukaryotic	NULL
cells	NULL
.	NULL

Methods	NULL
Enzymol	NULL
.	NULL

,	NULL
151	NULL
:	NULL
382-397	NULL
,	NULL
1987.	NULL
.	NULL

Sun	NULL
,	NULL
S-C.	NULL
,	NULL
Ganchi	NULL
,	NULL
P.	NULL
A.	NULL
,	NULL
Ballard	NULL
,	NULL
D.	NULL
W.	NULL
,	NULL
and	NULL
Greene	NULL
,	NULL
W.	NULL
C.	NULL
NF-	NULL
«	NULL
B	NULL
controls	NULL
expres-	NULL
sion	NULL
of	NULL
inhibitor	NULL
IxBa	NULL
:	NULL
evidence	NULL
for	NULL
an	NULL
inducible	NULL
autoregulatory	NULL
pathway	NULL
.	NULL

Science	NULL
(	NULL
Washington	NULL
DC	NULL
)	NULL
,	NULL
259	NULL
:	NULL
1912-1915	NULL
,	NULL
1993	NULL
.	NULL

Nabel	NULL
,	NULL
G.	NULL
,	NULL
and	NULL
Baltimore	NULL
,	NULL
D.	NULL
An	NULL
inducible	NULL
transcription	NULL
factor	NULL
activates	NULL
expression	NULL
of	NULL
human	NULL
immunodeficiency	NULL
virus	NULL
in	NULL
T	NULL
cells	NULL
.	NULL

Nature	NULL
(	NULL
Lond	NULL
.	NULL
)	NULL

,	NULL
326	NULL
:	NULL
711-713	NULL
,	NULL
1987.	NULL
.	NULL

Schreck	NULL
,	NULL
R.	NULL
,	NULL
Reiber	NULL
,	NULL
P.	NULL
,	NULL
and	NULL
Bacuerle	NULL
P.	NULL
A.	NULL
Reactive	NULL
oxygen	NULL
intermediates	NULL
as	NULL
appar-	NULL
ently	NULL
widely	NULL
used	NULL
messengers	NULL
in	NULL
the	NULL
activation	NULL
of	NULL
the	NULL
NF-KB	NULL
transcription	NULL
factor	NULL
and	NULL
HIV-1	NULL
.	NULL

EMBO	NULL
,	NULL
10	NULL
:	NULL
2247-2258	NULL
,	NULL
1991	NULL
.	NULL

Uckum	NULL
,	NULL
F.	NULL
M.	NULL
,	NULL
Schieven	NULL
,	NULL
G.	NULL
L.	NULL
,	NULL
Tuel-Ahigren	NULL
,	NULL
L.	NULL
M.	NULL
,	NULL
Dibirdik	NULL
,	NULL
L.	NULL
,	NULL
Myers	NULL
,	NULL
D.	NULL
E.	NULL
,	NULL
Ledbetter	NULL
,	NULL
J	NULL
.	NULL

A.	NULL
,	NULL
and	NULL
Song	NULL
,	NULL
C.	NULL
W.	NULL
Tyrosine	NULL
phosphorylation	NULL
is	NULL
a	NULL
mandatory	NULL
proximal	NULL
step	NULL
in	NULL
radiation-induced	NULL
activation	NULL
of	NULL
the	NULL
protein	NULL
kinase	NULL
C	NULL
signaling	NULL
pathway	NULL
in	NULL
human	NULL
B-lymphocyte	NULL
precursors	NULL
.	NULL

Proc	NULL
.	NULL

Natl	NULL
.	NULL

Acad	NULL
.	NULL

Sci	NULL
.	NULL

USA	NULL
,	NULL
90	NULL
:	NULL
252-256	NULL
,	NULL
1993	NULL
.	NULL

Devary	NULL
,	NULL
Y.	NULL
,	NULL
Rosette	NULL
,	NULL
C.	NULL
,	NULL
DiDonato	NULL
,	NULL
J	NULL
.	NULL

A.	NULL
,	NULL
and	NULL
Karin	NULL
,	NULL
M.	NULL
NF-	NULL
«	NULL
B	NULL
activation	NULL
by	NULL
ultraviolet	NULL
light	NULL
not	NULL
dependent	NULL
on	NULL
a	NULL
nuclear	NULL
signal	NULL
.	NULL

Science	NULL
(	NULL
Washington	NULL
DC	NULL
)	NULL
,	NULL
267	NULL
:	NULL
1442-1445	NULL
,	NULL
1993	NULL
.	NULL

Casnellie	NULL
,	NULL
J.	NULL
E.	NULL
Protein	NULL
kinase	NULL
inhibitors	NULL
:	NULL
probes	NULL
for	NULL
the	NULL
functions	NULL
of	NULL
protein	NULL
phosphorylation	NULL
.	NULL

Adv	NULL
.	NULL

Pharmacol	NULL
.	NULL

,	NULL
22	NULL
:	NULL
157-205	NULL
,	NULL
1991.	NULL
.	NULL

Cohen	NULL
,	NULL
B.	NULL
,	NULL
Yoakim	NULL
,	NULL
M.	NULL
,	NULL
Piwnica-Worms	NULL
,	NULL
H.	NULL
,	NULL
Roberts	NULL
,	NULL
T.	NULL
M.	NULL
,	NULL
and	NULL
Schaffhausen	NULL
,	NULL
B.	NULL
S.	NULL
Tyrosine	NULL
phosphorylation	NULL
is	NULL
a	NULL
signal	NULL
for	NULL
the	NULL
trafficking	NULL
of	NULL
pp85	NULL
,	NULL
an	NULL
85-kDa	NULL
phosphorylated	NULL
polypeptide	NULL
associated	NULL
with	NULL
phosphatidylinositol	NULL
kinase	NULL
activity	NULL
.	NULL

Proc	NULL
.	NULL

Natl	NULL
.	NULL

41	NULL
.	NULL

42	NULL
.	NULL

43	NULL
.	NULL

45	NULL
.	NULL

47	NULL
.	NULL

49	NULL
.	NULL

1430	NULL
Acad	NULL
.	NULL

Sci	NULL
.	NULL

USA	NULL
,	NULL
87	NULL
:	NULL
4458-4462	NULL
,	NULL
1990	NULL
.	NULL

Kanakura	NULL
,	NULL
Y.	NULL
,	NULL
Druker	NULL
,	NULL
B.	NULL
,	NULL
DiCarlo	NULL
,	NULL
J.	NULL
,	NULL
Cannistra	NULL
,	NULL
S.	NULL
A.	NULL
,	NULL
and	NULL
Griffin	NULL
,	NULL
J.	NULL
D.	NULL
Phorbol	NULL
12-myristate	NULL
13-acetate	NULL
inhibits	NULL
granulocyte-macrophage	NULL
colony	NULL
stimulating	NULL
factor-induced	NULL
protein	NULL
tyrosine	NULL
phosphorylation	NULL
in	NULL
a	NULL
human	NULL
factor-dependent	NULL
hematopoietic	NULL
cell	NULL
line	NULL
.	NULL

J.	NULL
Biol	NULL
.	NULL

Chem	NULL
.	NULL

,	NULL
266	NULL
:	NULL
490-495	NULL
,	NULL
1991	NULL
.	NULL

Bruder	NULL
,	NULL
J.	NULL
T.	NULL
,	NULL
Heidecker	NULL
,	NULL
G.	NULL
,	NULL
and	NULL
Rapp	NULL
,	NULL
U.	NULL
R.	NULL
Serum-	NULL
,	NULL
TPA-	NULL
,	NULL
and	NULL
Ras-induced	NULL
expression	NULL
from	NULL
Ap-1/Ets-driven	NULL
promoters	NULL
.	NULL

Genes	NULL
&	NULL
Dev	NULL
.	NULL

,	NULL
6	NULL
:	NULL
545-556	NULL
,	NULL
1992	NULL
.	NULL

Finco	NULL
,	NULL
T.	NULL
S.	NULL
,	NULL
and	NULL
Baldwin	NULL
,	NULL
A.	NULL
S.	NULL
xB	NULL
site-dependent	NULL
induction	NULL
of	NULL
gene	NULL
expression	NULL
by	NULL
diverse	NULL
inducers	NULL
of	NULL
xB	NULL
requires	NULL
Raf-1	NULL
.	NULL

J.	NULL
Biol	NULL
.	NULL

Chem	NULL
.	NULL

,	NULL
268	NULL
:	NULL
17676-17679	NULL
,	NULL
1993.	NULL
.	NULL

Folkman	NULL
,	NULL
J.	NULL
Tumor	NULL
angiogenesis	NULL
.	NULL

/n	NULL
:	NULL
E.	NULL
F.	NULL
J.	NULL
Holland	NULL
,	NULL
R.	NULL
Bast	NULL
,	NULL
D.	NULL
Kufe	NULL
,	NULL
R.	NULL
L.	NULL
Morton	NULL
,	NULL
and	NULL
R.	NULL
R.	NULL
Weichselbaum	NULL
(	NULL
eds	NULL
.	NULL
)	NULL

,	NULL
Cancer	NULL
Medicine	NULL
,	NULL
Ed	NULL
.	NULL

3	NULL
,	NULL
pp	NULL
.	NULL

153-170	NULL
.	NULL

Philadelphia	NULL
:	NULL
Lea	NULL
&	NULL
Febiger	NULL
,	NULL
1993	NULL
.	NULL

Hansen	NULL
,	NULL
S.	NULL
,	NULL
Nerlov	NULL
,	NULL
C.	NULL
,	NULL
Zabel	NULL
,	NULL
U.	NULL
,	NULL
Verde	NULL
,	NULL
P.	NULL
,	NULL
Johnsen	NULL
,	NULL
M.	NULL
,	NULL
Bacuerle	NULL
,	NULL
P.	NULL
A.	NULL
,	NULL
and	NULL
Blasi	NULL
,	NULL
F.	NULL
A	NULL
novel	NULL
complex	NULL
between	NULL
the	NULL
p65	NULL
subunit	NULL
of	NULL
NF-	NULL
«	NULL
B	NULL
and	NULL
c-Rel	NULL
binds	NULL
to	NULL
a	NULL
DNA	NULL
element	NULL
involved	NULL
in	NULL
the	NULL
phorbol	NULL
ester	NULL
induction	NULL
of	NULL
the	NULL
human	NULL
urokinase	NULL
gene	NULL
.	NULL

EMBO	NULL
,	NULL
11	NULL
:	NULL
205-213	NULL
,	NULL
1992.	NULL
.	NULL

Schutze	NULL
,	NULL
S.	NULL
,	NULL
Machleidt	NULL
,	NULL
T.	NULL
,	NULL
and	NULL
Kronke	NULL
,	NULL
M.	NULL
Mechanisms	NULL
of	NULL
tumor	NULL
necrosis	NULL
factor	NULL
action	NULL
.	NULL

Semin	NULL
.	NULL

Oncol	NULL
.	NULL

,	NULL
79	NULL
:	NULL
16-14	NULL
,	NULL
1992	NULL
.	NULL

Takao	NULL
,	NULL
S.	NULL
,	NULL
and	NULL
Jacob	NULL
,	NULL
C.	NULL
Mouse	NULL
tumor	NULL
necrosis	NULL
factor	NULL
receptor	NULL
type	NULL
I	NULL
:	NULL
genomic	NULL
structure	NULL
,	NULL
polymorphism	NULL
,	NULL
and	NULL
identification	NULL
of	NULL
regulatory	NULL
regions	NULL
.	NULL

Int	NULL
.	NULL

Immunol	NULL
.	NULL

,	NULL
5	NULL
:	NULL
775-782	NULL
,	NULL
1993.	NULL
.	NULL

Higgins	NULL
,	NULL
K.	NULL
A.	NULL
,	NULL
Perez	NULL
,	NULL
J.	NULL
R.	NULL
,	NULL
Coleman	NULL
,	NULL
T.	NULL
A.	NULL
,	NULL
Dorshkind	NULL
,	NULL
K.	NULL
,	NULL
McComas	NULL
,	NULL
W.	NULL
A.	NULL
,	NULL
Sariento	NULL
,	NULL
U.	NULL
M.	NULL
,	NULL
Rosen	NULL
,	NULL
C.	NULL
A.	NULL
,	NULL
and	NULL
Narayanan	NULL
,	NULL
R.	NULL
Antisense	NULL
inhibition	NULL
of	NULL
the	NULL
p63	NULL
subunit	NULL
of	NULL
NF-kB	NULL
blocks	NULL
tumorigenicity	NULL
and	NULL
causes	NULL
tumor	NULL
regression	NULL
.	NULL

Proc	NULL
.	NULL

Natl	NULL
.	NULL

Acad	NULL
.	NULL

Sci	NULL
.	NULL

USA	NULL
,	NULL
90	NULL
:	NULL
9901-9905	NULL
,	NULL
1993	NULL
.	NULL

Brown	NULL
,	NULL
J.	NULL
M.	NULL
,	NULL
and	NULL
Giaccia	NULL
,	NULL
A.	NULL
J.	NULL
Tumor	NULL
hypoxia	NULL
:	NULL
the	NULL
picture	NULL
has	NULL
changed	NULL
in	NULL
the	NULL
1990	NULL
's	NULL
.	NULL

Int	NULL
.	NULL

J.	NULL
Radiat	NULL
.	NULL

Oncol	NULL
.	NULL

Biol	NULL
.	NULL

Phys	NULL
.	NULL

,	NULL
in	NULL
press	NULL
,	NULL
1994	NULL
.	NULL

Downloaded	NULL
from	NULL
cancerres.aacrjournals.org	NULL
on	NULL
May	NULL
10	NULL
,	NULL
2019	NULL
.	NULL

©	NULL
1994	NULL
American	NULL
Association	NULL
for	NULL
Cancer	NULL
Research	NULL
.	NULL

AAGR	NULL
American	NULL
Association	NULL
for	NULL
Cancer	NULL
Research	NULL
Cancer	NULL
Research	NULL
The	NULL
Journal	NULL
of	NULL
Cancer	NULL
Research	NULL
(	NULL
1916-1930	NULL
)	NULL
|	NULL
The	NULL
American	NULL
Journal	NULL
of	NULL
Cancer	NULL
(	NULL
1931-1940	NULL
)	NULL
Hypoxia	NULL
Causes	NULL
the	NULL
Activation	NULL
of	NULL
Nuclear	NULL
Factor	NULL
xB	NULL
through	NULL
the	NULL
Phosphorylation	NULL
of	NULL
|	NULL
xBa	NULL
on	NULL
Tyrosine	NULL
Residues	NULL
Albert	NULL
C.	NULL
Koong	NULL
,	NULL
Eunice	NULL
Y.	NULL
Chen	NULL
and	NULL
Amato	NULL
J.	NULL
Giaccia	NULL
Cancer	NULL
Res	NULL
1994	NULL
;	NULL
54:1	NULL
425-1430	NULL
.	NULL

Updated	NULL
version	NULL
_	NULL
Access	NULL
the	NULL
most	NULL
recent	NULL
version	NULL
of	NULL
this	NULL
article	NULL
at	NULL
:	NULL
http	NULL
:	NULL
//cancerres.aacrjournals.org/content/54/6/1	NULL
425	NULL
E-mail	NULL
alerts	NULL
_	NULL
Sign	NULL
up	NULL
to	NULL
receive	NULL
free	NULL
email-alerts	NULL
related	NULL
to	NULL
this	NULL
article	NULL
or	NULL
journal	NULL
.	NULL

Reprints	NULL
and	NULL
_	NULL
To	NULL
order	NULL
reprints	NULL
of	NULL
this	NULL
article	NULL
or	NULL
to	NULL
subscribe	NULL
to	NULL
the	NULL
journal	NULL
,	NULL
contact	NULL
the	NULL
AACR	NULL
Publications	NULL
Subscriptions	NULL
_	NULL
Department	NULL
at	NULL
pubs	NULL
@	NULL
aacr.org	NULL
.	NULL

Permissions	NULL
_	NULL
To	NULL
request	NULL
permission	NULL
to	NULL
re-use	NULL
all	NULL
or	NULL
part	NULL
of	NULL
this	NULL
article	NULL
,	NULL
use	NULL
this	NULL
link	NULL
http	NULL
:	NULL
//cancerres.aacrjournals.org/content/54/6/1425	NULL
.	NULL

Click	NULL
on	NULL
``	NULL
Request	NULL
Permissions	NULL
``	NULL
which	NULL
will	NULL
take	NULL
you	NULL
to	NULL
the	NULL
Copyright	NULL
Clearance	NULL
Center	NULL
's	NULL
(	NULL
CCC	NULL
)	NULL
Rightslink	NULL
site	NULL
.	NULL

Downloaded	NULL
from	NULL
cancerres.aacrjournals.org	NULL
on	NULL
May	NULL
10	NULL
,	NULL
2019	NULL
.	NULL

©	NULL
1994	NULL
American	NULL
Association	NULL
for	NULL
Cancer	NULL
Research	NULL
.	NULL

